Liste modèle des médicaments essentiels

BCG vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against tuberculosis

Ebola vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against certain single viral diseases

Japanese encephalitis vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against certain single viral diseases

Medicines for COVID-19

Section	Indications
Medicines for COVID-19 ◦ Refer to WHO living guidelines	COVID-19

Abacavir

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Solid: 300 mg tablet (as sulfate)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Abacavir + dolutegravir + lamivudine

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid > tablet: 60 mg (as sulfate) + 5 mg + 30 mg (dispersible, scored)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Abacavir + lamivudine

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Abacavir + lamivudine + lopinavir + ritonavir

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Abemaciclib

Section	Indications
Targeted therapies	Therapeutic equivalent to palbociclib pour Other specified malignant neoplasms of breast

Abiraterone

Section	Indications
Hormones and antihormones ◦ Oral > Solid: 250 mg; 500 mg	Malignant neoplasms of prostate

Acamprosate calcium

Section	Indications
Medicines for alcohol use disorders ◦ Oral > Solid > tablet: 333 mg	Disorders due to use of alcohol

Acenocoumarol

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to warfarin pour Venous thromboembolism Therapeutic equivalent to warfarin pour Cerebral ischaemic stroke due to embolic occlusion Therapeutic equivalent to warfarin pour Atrial fibrillation Therapeutic equivalent to warfarin pour Other specified diseases of arteries or arterioles

Acetazolamide

Section	Indications
Ophthalmological preparations > Miotics and antiglaucoma medicines ◦ Oral > Solid: 250 mg	Primary open-angle glaucoma

Acetic acid

Section	Indications
Ear, nose and throat medicines [c] ◦ Local > Otological > drops: 2% solution	Infectious diseases of external ear

Acetylcysteine

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule ◦ Oral > Liquid: 10%; 20%	Acute or subacute hepatic failure Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs

Acetylsalicylic acid

Section	Indications
Medicines for acute migraine attacks ◦ Oral > Solid: 300 to 500 mg	Migraine
Anti-platelet medicines ◦ Oral > Solid: 100 mg	Acute myocardial infarction Cerebral ischaemic stroke
Medicines for juvenile joint diseases ◦ Local > Rectal > Suppository: 150 mg; 300 mg ◦ Oral > Solid > dispersible tablet: 75 mg; 300 mg; 500 mg ◦ Oral > Solid > tablet: 75 to 500 mg	Mucocutaneous lymph node syndrome Juvenile idiopathic arthritis Acute rheumatic fever without mention of heart involvement
Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) ◦ Oral > Solid: 100 to 500 mg ◦ Local > Rectal > Suppository: 50 to 150 mg	Pain

Acetylsalicylic acid + atorvastatin + ramipril

Section	Indications
Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease ◦ Oral > Solid > tablet: 100 mg + 20 mg + 2.5 mg; 100 mg + 20 mg + 5 mg; 100 mg + 20 mg + 10 mg; 100 mg + 40 mg + 2.5 mg; 100 mg + 40 mg + 5 mg; 100 mg + 40 mg + 10 mg	Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke

Acetylsalicylic acid + simvastatin + ramipril + atenolol + hydrochlorothiazide

Section	Indications
Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease ◦ Oral > Solid > tablet: 100 mg + 20 mg + 5 mg + 50 mg + 12.5 mg	Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke

Aciclovir

Section	Indications
Ophthalmological preparations > Anti-infective agents ◦ Local > Ophthalmological > Ointment: 3% w/w	Herpes simplex keratitis
Antiherpes medicines ◦ Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium) ◦ Oral > Liquid: 200 mg per 5 mL ◦ Oral > Solid: 200 mg tablet ◦ Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium diihydrate); 25 mg per mL in vial solution for infusion (as sodium)	Zoster Herpes simplex infections Varicella
Medicines for viral central nervous system infections ◦ Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium) ◦ Oral > Liquid: 200 mg per 5 mL ◦ Oral > Solid: 200 mg tablet ◦ Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium diihydrate); 25 mg per mL in vial solution for infusion (as sodium)	Zoster Herpes simplex infections Varicella

Aclidinium

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to tiotropium bromide pour Chronic obstructive pulmonary disease

Activated charcoal

Section	Indications
Antidotes and other substances used in poisonings > Non-specific ◦ Oral > Liquid: 50 mg granules for oral suspension	Unspecified injury, poisoning or certain other consequences of external causes

Adalimumab

Section	Indications
Immunomodulators for non-malignant disease ◦ Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL	Axial spondyloarthritis Crohn disease site Rheumatoid arthritis
Medicines for juvenile joint diseases ◦ Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL	Juvenile idiopathic arthritis
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Parenteral > General injections > SC: 10 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.; 80 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.	Psoriasis of unspecified type

Afatinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib pour Other specified malignant neoplasms of bronchus or lung

Albendazole

Section	Indications
Intestinal anthelminthics ◦ Oral > Solid > tablet: 400 mg (chewable, scored)	Echinococcosis Cysticercosis Hookworm diseases Trichuriasis Ascariasis Enterobiasis
Cysticidal medicines ◦ Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)	Other specified echinococcosis Cysticercosis of central nervous system
Antifilarials ◦ Oral > Solid > tablet: 400 mg (chewable, scored)	Lymphatic filariasis

Alcohol based hand rub

Section	Indications
Disinfectants ◦ Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol	Denatured alcohol

Alcuronium

Section	Indications
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors ◦ Parenteral > General injections > IV: 5 mg per mL in 2 mL ampoule (alcuronium chloride)	Muscle relaxants

Alfacalcidol

Section	Indications
Medicines for endocrine disorders ◦ Oral > Liquid: 2 µg per mL ◦ Oral > Solid > capsule: 0.25 µg; 1 µg	Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport

All-trans retinoic acid

Section	Indications
Targeted therapies ◦ Oral > Solid: 10 mg capsule	Acute myeloid leukaemia with recurrent genetic abnormalities

Allopurinol

Section	Indications
Medicines used to treat gout ◦ Oral > Solid: 100 mg	Gout
Supportive medicines ◦ Parenteral > General injections > IV: 500 mg (as sodium) powder for injection ◦ Oral > Solid: 100 mg; 300 mg	Tumour lysis syndrome

Alprostadil (prostaglandin E1)

Section	Indications
Medicines administered to the neonate [c] ◦ Parenteral > General injections > IV: 0.5 mg per mL in alcohol	Other specified congenital anomaly of great arteries including arterial duct

Alteplase

Section	Indications
Thrombolytic medicines ◦ Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection	Cerebral ischaemic stroke

Amidotrizoate

Section	Indications
Diagnostic agents > Radiocontrast media ◦ Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)	Amidotrizoate

Amikacin

Section	Indications
Ophthalmological preparations > Anti-infective agents	Therapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis
Access group antibiotics ◦ Parenteral > General injections > unspecified: 50 mg per mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate) ◦ Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate) ◦ Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)	**Premier choix** Neutropaenia (high-risk) co-prescrite avec cefotaxime Acute pyelonephritis (severe) co-prescrite avec cefotaxime Inflammatory or other diseases of prostate (severe) co-prescrite avec ceftriaxone Acute pyelonephritis (severe) co-prescrite avec ceftriaxone Inflammatory or other diseases of prostate (severe)
Antituberculosis medicines ◦ Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)	Multi-drug resistant Mycobacterium tuberculosis

Amiloride

Section	Indications
Diuretics ◦ Oral > Solid: 5 mg (hydrochloride)	Oedema Ascites

Amiodarone

Section	Indications
Antiarrhythmic medicines ◦ Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride) ◦ Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)	Cardiac arrhythmia

Amitriptyline

Section	Indications
Medicines for migraine prophylaxis ◦ Oral > Solid > tablet: 25 mg	Migraine
Medicines for other common symptoms in palliative care ◦ Oral > Liquid: 25 mg per 5 mL ◦ Oral > Solid > tablet: 25 mg; 10 mg; 75 mg	Palliative care
Medicines for depressive disorders ◦ Oral > Solid: 25 mg; 75 mg	Depressive disorders

Amlodipine

Section	Indications
Antihypertensive medicines ◦ Oral > Solid: 5 mg (as maleate, mesylate or besylate)	Essential hypertension

Amodiaquine

Section	Indications
Antimalarial medicines > Medicines for curative treatment ◦ Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Amodiaquine - sulfadoxine + pyrimethamine

Section	Indications
Antimalarial medicines > Medicines for chemoprevention ◦ Oral > Solid > dispersible tablet: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package; 75 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 150 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package	Malaria

Amoxicillin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid ◦ Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection ◦ Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate) ◦ Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate) ◦ Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate) ◦ Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid	**Premier choix** Acute pharyngitis Periapical abscess without sinus Acute sinusitis Acute otitis media Chronic obstructive pulmonary disease with acute exacerbation Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec gentamicin Sepsis without septic shock **Second choix** Bacterial meningitis **Autres indications** Bacterial infection of unspecified site Infectious cystitis
Medicines for bacterial central nervous system infections ◦ Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid ◦ Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection ◦ Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate) ◦ Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)	**Second choix** Bacterial meningitis

Amoxicillin + clavulanic acid

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection ◦ Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid ◦ Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt) ◦ Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt) ◦ Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)	**Premier choix** Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute sinusitis Other specified pneumonia (Hospital-acquired pneumonia) Chronic obstructive pulmonary disease with acute exacerbation Neutropaenia (low-risk) Peritoneal abscess (mild-moderate) Peritonitis (mild-moderate) Infectious cystitis Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Bacterial pneumonia (Community-acquired pneumonia - severe) Bacterial infection of joint Acute otitis media Other specified prophylactic measures Osteomyelitis or osteitis **Autres indications** Bacterial infection of unspecified site
Antituberculosis medicines ◦ Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid ◦ Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt) ◦ Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)	Multi-drug resistant Mycobacterium tuberculosis

Amphotericin B

Section	Indications
Antifungal medicines ◦ Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)	Candidosis Blastomycosis Cryptococcosis Coccidioidomycosis Aspergillosis Sporotrichosis Histoplasmosis
Antileishmaniasis medicines ◦ Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)	Visceral leishmaniasis

Ampicillin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection ◦ Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension ◦ Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)	**Premier choix** Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec gentamicin Sepsis without septic shock co-prescrite avec gentamicin Peritoneal abscess (mild-moderate) co-prescrite avec gentamicin Peritoneal abscess (severe) co-prescrite avec gentamicin Peritonitis (mild-moderate) co-prescrite avec gentamicin Peritonitis (severe) **Second choix** Bacterial meningitis **Autres indications** Bacterial infection of unspecified site
Medicines for bacterial central nervous system infections ◦ Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection	**Second choix** Bacterial meningitis

Anakinra

Section	Indications
Medicines for juvenile joint diseases ◦ Parenteral > General injections > SC: 100 mg per 0.67 mL in pre-filled syringe	Juvenile systemic arthritis

Anastrozole

Section	Indications
Hormones and antihormones ◦ Oral > Solid: 1 mg tablet	Malignant neoplasms of breast Other specified malignant neoplasms of breast
Ovulation inducers ◦ Oral > Solid: 1 mg tablet	Therapeutic equivalent to letrozole pour Female infertility without specification whether primary or secondary

Anidulafungin

Section	Indications
Antifungal medicines	Therapeutic equivalent to micafungin pour Systemic or invasive candidosis

Ansuvimab

Section	Indications
Medicines for Ebola virus disease ◦ Parenteral > General injections > IV: 400 mg powder for injection	Ebola virus disease

Anti-D immunoglobulin

Section	Indications
Human immunoglobulins ◦ Parenteral > General injections > IV: 250 µg in single-dose vial ◦ Parenteral > General injections > IM: 250 µg in single-dose vial	Maternal care for red cell antibodies Rh incompatibility reaction

Anti-rabies immunoglobulin

Section	Indications
Human immunoglobulins ◦ Parenteral > General injections > IM: 150 IU per mL in vial ◦ Parenteral > Locoregional injections > Other: 150 IU per mL in vial	Rabies

Anti-rabies virus monoclonal antibodies

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)	Rabies

Anti-tetanus immunoglobulin

Section	Indications
Human immunoglobulins ◦ Parenteral > General injections > IM: 500 IU in vial	Tetanus

Antirabies hyperimmune serum

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ Parenteral > General injections > unspecified: 1000 IU in 5 mL ampoule	Rabies

Antivenom immunoglobulin

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ Parenteral > General injections > IV:	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Antivenom sera

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ Parenteral > General injections > IV:	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Apixaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation Therapeutic equivalent to dabigatran pour Venous thromboembolism

Aprepitant

Section	Indications
Antiemetic medicines ◦ Oral > Liquid: 125 mg powder for oral suspension (in sachet) ◦ Oral > Solid > capsule: 80 mg; 125 mg; 165 mg	Nausea or vomiting

Aripiprazole

Section	Indications
Medicines for psychotic disorders ◦ Parenteral > General injections > IM: 300 mg powder and solvent for suspension; 400 mg powder and solvent for suspension	Therapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders Therapeutic equivalent to paliperidone pour Schizophrenia or other primary psychotic disorders

Arpraziquantel

Section	Indications
Antischistosomals and other antitrematode medicines ◦ Oral > Solid > dispersible tablet: 150 mg	Therapeutic equivalent to praziquantel pour Schistosomiasis

Arsenic trioxide

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion	Acute myeloid leukaemia with recurrent genetic abnormalities

Artemether

Section	Indications
Antimalarial medicines > Medicines for curative treatment ◦ Parenteral > General injections > IM: 20 mg per mL in 1 mL ampoule (oily injection); 40 mg per mL in 1 mL ampoule (oily injection)	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Artemether + lumefantrine

Section	Indications
Antimalarial medicines > Medicines for curative treatment ◦ Oral > Solid > dispersible tablet: 20 mg + 120 mg ◦ Oral > Solid > tablet: 20 mg + 120 mg	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Artesunate

Section	Indications
Antimalarial medicines > Medicines for curative treatment ◦ Parenteral > General injections > IV: 60 mg in vial powder for injection; 30 mg in vial powder for injection; 120 mg in vial powder for injection ◦ Local > Rectal > Other: 100 mg capsules	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Artesunate + amodiaquine

Section	Indications
Antimalarial medicines > Medicines for curative treatment ◦ Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg ◦ Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg tablet	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Artesunate + mefloquine

Section	Indications
Antimalarial medicines > Medicines for curative treatment ◦ Oral > Solid > tablet: 25 mg + 50 mg (as hydrochloride); 100 mg + 200 mg (as hydrochloride)	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Artesunate + pyronaridine

Section	Indications
Antimalarial medicines > Medicines for curative treatment ◦ Oral > Solid > tablet: 60 mg + 180 mg (tetraphosphate) ◦ Oral > Solid > granules: 20 mg + 60 mg (tetraphosphate)	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Artesunate - sulfadoxine + pyrimethamine

Section	Indications
Antimalarial medicines > Medicines for curative treatment ◦ Oral > Solid > tablet: 50 mg [3] + 500 mg + 25 mg [1] in copackage (scored)	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Ascorbic acid

Section	Indications
Vitamins and minerals ◦ Oral > Solid: 50 mg	Scurvy

Asparaginase

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > unspecified: 10000 IU in vial powder for injection ◦ Powder for injection: 10 000 IU in vial.	Lymphoid leukaemia, not elsewhere classified Unspecified malignant neoplasms of unspecified sites

Atazanavir

Section	Indications
Antiretrovirals > Protease inhibitors ◦ Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Atazanavir + ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors ◦ Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Atenolol

Section	Indications
Antianginal medicines ◦ Oral > Solid: 50 mg; 100 mg	Angina pectoris
Antihypertensive medicines ◦ Oral > Solid: 50 mg; 100 mg	Essential hypertension Therapeutic equivalent to bisoprolol pour Essential hypertension

Atezolizumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion ◦ Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion	Therapeutic equivalent to pembrolizumab pour Adenocarcinoma of stomach Hepatocellular carcinoma of liver Therapeutic equivalent to pembrolizumab pour Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of bronchus or lung

Atoltivimab + maftivimab + odesivimab

Section	Indications
Medicines for Ebola virus disease ◦ Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial	Ebola virus disease

Atorvastatin

Section	Indications
Lipid-lowering agents	Therapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis

Atorvastatin + perindopril + amlodipine

Section	Indications
Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease ◦ Oral > Solid > tablet: 20 mg + 5 mg + 5 mg; 20 mg + 10 mg + 10 mg; 40 mg + 5 mg + 5 mg; 40 mg + 10 mg + 10 mg	Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke

Atracurium

Section	Indications
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors ◦ Parenteral > General injections > IV: 10 mg per mL (besylate)	Therapeutic equivalent to vecuronium pour Muscle relaxants Muscle relaxants

Atropine

Section	Indications
Diagnostic agents > Ophthalmic medicines	Therapeutic equivalent to tropicamide pour Cycloplegic drug
Ophthalmological preparations > Mydriatics ◦ Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)	Anterior uveitis
Antidotes and other substances used in poisonings > Specific ◦ Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule or vial (sulfate)	Exposure to or harmful effects of undetermined intent of pesticides
Preoperative medication and sedation for short-term procedures ◦ Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule or vial (sulfate); 400 µg per mL in 1 mL ampoule or vial (sulfate)	Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics

Axicabtagene ciloleucel

Section	Indications
Antineoplastics and supportive medicines ◦ Cell suspension for infusion: 2 × 10*6 anti-CD19 CAR-positive viable T-cells per kg of body weight.	Diffuse large B-cell lymphomas

Axitinib

Section	Indications
Targeted therapies ◦ Oral > Solid > tablet: 1 mg; 3 mg; 5 mg	Renal cell carcinoma of kidney, except renal pelvis

Azacitidine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 100 mg in vial powder for injection	Myeloid leukaemia

Azathioprine

Section	Indications
Disease-modifying anti-rheumatic drugs (DMARDs) ◦ Oral > Solid > tablet: 50 mg (scored)	Rheumatoid arthritis, serology unspecified Psoriatic arthritis
Immunomodulators for non-malignant disease ◦ Oral > Solid > tablet: 50 mg (scored) ◦ Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt) ◦ Oral > Liquid: 10 mg per mL ◦ Oral > Solid > tablet: 25 mg; 50 mg (scored)	Relapsing-remitting multiple sclerosis Failure or rejection of transplanted organs or tissues

Azithromycin

Section	Indications
Watch group antibiotics ◦ Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid ◦ Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)	**Premier choix** Cholera Cholera [children] Paratyphoid fever Chlamydia trachomatis Typhoid fever Yaws Trachoma co-prescrite avec ceftriaxone Gonococcal infection **Second choix** Infectious gastroenteritis or colitis without specification of infectious agent co-prescrite avec cefixime Gonococcal infection
Ophthalmological preparations > Anti-infective agents ◦ Local > Ophthalmological > Solution (eye drops): 1.5% eye drops	Trachoma

Aztreonam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection	Other specified bacterial diseases

Baclofen

Section	Indications
Medicines for cerebral palsy ◦ Oral > Liquid: 10 mg per 5 mL ◦ Parenteral > Locoregional injections > Intrathecal: 500 µg per mL in ampoule ◦ Oral > Solid > tablet: 10 mg	Spastic cerebral palsy

Barium sulfate

Section	Indications
Diagnostic agents > Radiocontrast media ◦ Oral > Liquid: Aqueous suspension	Barium sulfate with suspending agents

Beclometasone

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease ◦ Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae)	Asthma Therapeutic equivalent to budesonide pour Asthma

Beclometasone + formoterol

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to budesonide + formoterol pour Asthma

Bedaquiline

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > tablet: 100 mg tablet; 20 mg tablet	Multi-drug resistant Mycobacterium tuberculosis

Beinaglutide

Section	Indications
Hypoglycaemic agents	Therapeutic equivalent to semaglutide pour Obesity

Bendamustine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL	Chronic lymphocytic leukaemia or small lymphocytic lymphoma Follicular lymphoma

Benzathine benzylpenicillin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection	**Premier choix** Congenital syphilis [children] Syphilis **Autres indications** Bacterial infection of unspecified site

Benznidazole

Section	Indications
American trypanosomiasis ◦ Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg	Chagas disease

Benzoic acid + salicylic acid

Section	Indications
Dermatological medicines > Antifungal medicines ◦ Local > Topical > Cream: 6% + 3% ◦ Local > Topical > Ointment: 6% + 3%	Fungal infection of the skin

Benzoyl peroxide

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Local > Topical > Cream: 5% ◦ Local > Topical > Lotion: 5%	Acne

Benzyl benzoate

Section	Indications
Dermatological medicines > Scabicides and pediculicides ◦ Local > Topical > Lotion: 25%	Pediculosis corporis Pediculosis capitis Pthiriasis Scabies

Benzylpenicillin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt) ◦ Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)	**Premier choix** Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Congenital syphilis [children] Syphilis co-prescrite avec gentamicin Sepsis without septic shock **Second choix** Bacterial meningitis **Autres indications** Bacterial infection of unspecified site
Medicines for bacterial central nervous system infections ◦ Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)	**Second choix** Bacterial meningitis

Beractant

Section	Indications
Medicines administered to the neonate [c] ◦ Respiratory > Suspension: 25 mg per mL for intratracheal instillation	Respiratory distress syndrome of newborn

Betamethasone

Section	Indications
Dermatological medicines > Anti-inflammatory and antipruritic medicines ◦ Local > Topical > Cream: 0.1% (as valerate) ◦ Local > Topical > Ointment: 0.1% (as valerate)	Dermatitis or eczema Pruritus due to skin disorder Psoriasis of unspecified type Lichen planus

Bevacizumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion	Hepatocellular carcinoma of liver
Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations ◦ Parenteral > Locoregional injections > Intravitreal: 25 mg per mL	Age-related macular degeneration

Bicalutamide

Section	Indications
Hormones and antihormones ◦ Oral > Solid: 50 mg	Malignant neoplasms of prostate

Binimetinib

Section	Indications
Targeted therapies	Therapeutic equivalent to trametinib pour Other specified melanoma of skin

Biperiden

Section	Indications
Medicines for parkinsonism ◦ Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate) ◦ Oral > Solid: 2 mg tablet (hydrochloride)	Parkinson disease

Bisacodyl

Section	Indications
Laxatives	Therapeutic equivalent to senna pour Constipation

Bisoprolol

Section	Indications
Antianginal medicines ◦ Oral > Solid: 1.25 mg; 5 mg	Angina pectoris
Antihypertensive medicines ◦ Oral > Solid: 1.25 mg; 5 mg	Essential hypertension
Medicines for migraine prophylaxis ◦ Oral > Solid: 1.25 mg; 5 mg	Migraine
Antiarrhythmic medicines ◦ Oral > Solid: 1.25 mg; 5 mg	Cardiac arrhythmia
Medicines used in heart failure ◦ Oral > Solid: 1.25 mg; 5 mg	Heart failure

Bleomycin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)	Kaposi sarcoma of unspecified primary site Germ cell tumour of testis Other specified malignant neoplasms of the ovary Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma

Blinatumomab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial	B lymphoblastic leukaemia or lymphoma, not elsewhere classified

Bortezomib

Section	Indications
Targeted therapies ◦ Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection	Plasma cell myeloma

Brexpiprazole

Section	Indications
Medicines for depressive disorders ◦ Oral > Solid > tablet: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg	Depressive disorders

Bromocriptine

Section	Indications
Medicines for central nervous system disorders ◦ Oral > Solid: 2.5 mg; 5 mg	Parkinson disease
Medicines for disorders of the pituitary hormone system	Therapeutic equivalent to cabergoline pour Other specified benign neoplasm of endocrine glands

Budesonide

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease ◦ Respiratory > Inhalation > powder: 100 µg per actuation in dry powder inhaler; 200 µg per actuation in dry powder inhaler ◦ Respiratory > Inhalation > suspension: 100 µg per actuation in pressurized metered dose inhaler; 200 µg per actuation in pressurized metered dose inhaler	Asthma
Ear, nose and throat medicines [c] ◦ Local > Nasal > Spray: 32 µg per actuation; 64 µg per actuation	Allergic rhinitis

Budesonide + formoterol

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease ◦ Respiratory > Inhalation > powder: 100 µg + 6 µg per dose actuation in dry powder inhaler; 200 µg + 6 µg per dose actuation in dry powder inhaler	Asthma

Budesonide + salmeterol

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to budesonide + formoterol pour Asthma

Bumetanide

Section	Indications
Diuretics	Therapeutic equivalent to furosemide pour Anuria or oliguria Therapeutic equivalent to furosemide pour Oedema
Medicines used in heart failure	Therapeutic equivalent to furosemide pour Heart failure

Bupivacaine

Section	Indications
Local anaesthetics ◦ Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 8% glucose solution ◦ Parenteral > General injections > unspecified: 0.25% (hydrochloride); 0.5% (hydrochloride)	Local anaesthetics

Buprenorphine

Section	Indications
Medicines for opioid use disorders	Therapeutic equivalent to methadone pour Opioid dependence

Bupropion

Section	Indications
Medicines for nicotine use disorders ◦ Oral > Solid: 150 mg sustained-release (hydrochloride)	Nicotine dependence

C1 esterase inhibitor

Section	Indications
Human immunoglobulins ◦ Parenteral > General injections > IV: 500 IU in vial powder for injection	Hereditary angioedema

Cabergoline

Section	Indications
Medicines for disorders of the pituitary hormone system ◦ Oral > Solid > tablet: 0.5 mg; 1 mg	Other specified benign neoplasm of endocrine glands
Medicines for central nervous system disorders ◦ Oral > Solid > tablet: 0.5 mg	Parkinson disease

Caffeine citrate

Section	Indications
Medicines administered to the neonate [c] ◦ Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL) ◦ Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)	Apnoea of newborn

Calamine

Section	Indications
Dermatological medicines > Anti-inflammatory and antipruritic medicines ◦ Local > Topical > Lotion:	Pruritus

Calcipotriol

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Local > Topical > Cream: 50 µg per mL (0.005%) ◦ Local > Topical > Lotion: 50 µg per mL (0.005%) ◦ Local > Topical > Ointment: 50 µg per mL (0.005%)	Psoriasis of unspecified type

Calcitriol

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation	Therapeutic equivalent to calcipotriol pour Psoriasis of unspecified type
Medicines for endocrine disorders ◦ Oral > Solid > capsule: 0.25 µg; 0.5 µg	Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport

Calcium

Section	Indications
Vitamins and minerals ◦ Oral > Solid: 500 mg (elemental calcium)	Calcium deficiency

Calcium folinate (leucovorin calcium)

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule ◦ Oral > Solid > tablet: 15 mg; 5 mg; 25 mg ◦ Oral > Solid: 15 mg tablet ◦ Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule	Burkitt lymphoma including Burkitt leukaemia Osteosarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of rectum Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon Unspecified malignant neoplasms of unspecified sites Malignant trophoblastic neoplasms of placenta

Calcium gluconate

Section	Indications
Vitamins and minerals ◦ Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule	Tetany due to acute calcium deficiency
Antidotes and other substances used in poisonings > Specific ◦ Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule or vial (10%)	Hypermagnesaemia

Canagliflozin

Section	Indications
Hypoglycaemic agents	Therapeutic equivalent to empagliflozin pour Type 2 diabetes mellitus

Capecitabine

Section	Indications
Cytotoxic medicines ◦ Oral > Solid > tablet: 150 mg; 500 mg	Malignant neoplasms of rectum Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon Other specified malignant neoplasms of breast

Capreomycin

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 1000 mg powder for injection (vial)	Multi-drug resistant Mycobacterium tuberculosis

Captopril

Section	Indications
Medicines used in heart failure ◦ Oral > Solid: 25 mg	Heart failure

Carbachol

Section	Indications
Ophthalmological preparations > Miotics and antiglaucoma medicines	Therapeutic equivalent to pilocarpine pour Acute angle closure with pupillary block Therapeutic equivalent to pilocarpine pour Ocular hypertension Therapeutic equivalent to pilocarpine pour Primary open-angle glaucoma

Carbamazepine

Section	Indications
Antiseizure medicines ◦ Oral > Liquid: 100 mg per 5 mL ◦ Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)	Epilepsy or seizures
Medicines for neurological disorders ◦ Oral > Liquid: 100 mg per 5 mL ◦ Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored) ◦ Oral > Solid > capsule: 100 mg (extended-release); 200 mg (extended-release); 300 mg (extended-release)	Trigeminal neuralgia
Medicines for bipolar disorders ◦ Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg	Bipolar or related disorders

Carbetocin

Section	Indications
Uterotonics ◦ Parenteral > General injections > IV: 100 µg per mL (heat stable)	Postpartum haemorrhage

Carbimazole

Section	Indications
Thyroid hormones and antithyroid medicines	Therapeutic equivalent to methimazole pour Thyrotoxicosis

Carboplatin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL	Other specified gliomas of brain Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Malignant neoplasms of hypopharynx Malignant neoplasms of nasopharynx Malignant neoplasms of oropharynx Osteosarcoma of bone or articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Germ cell tumour of testis Malignant neoplasms of nasopharynx Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of breast Retinoblastoma Malignant neoplasms of kidney, except renal pelvis

Carmellose

Section	Indications
Ophthalmological preparations	Therapeutic equivalent to hypromellose pour Keratoconjunctivitis sicca

Carvedilol

Section	Indications
Antianginal medicines	Therapeutic equivalent to bisoprolol pour Angina pectoris
Antihypertensive medicines	Therapeutic equivalent to bisoprolol pour Essential hypertension
Antiarrhythmic medicines	Therapeutic equivalent to bisoprolol pour Cardiac arrhythmia
Medicines used in heart failure	Therapeutic equivalent to bisoprolol pour Heart failure

Caspofungin

Section	Indications
Antifungal medicines	Therapeutic equivalent to micafungin pour Systemic or invasive candidosis

Cefalexin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid ◦ Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate) ◦ Oral > Solid > dispersible tablet: 125 mg; 250 mg ◦ Oral > Solid: 250 mg (as monohydrate)	**Premier choix** Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Chronic obstructive pulmonary disease with acute exacerbation Acute pharyngitis **Autres indications** Bacterial infection of unspecified site

Cefazolin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection	**Premier choix** Other specified prophylactic measures co-prescrite avec metronidazole Other specified prophylactic measures **Second choix** Bacterial infection of joint Osteomyelitis or osteitis **Autres indications** Surgical site infection

Cefepime

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection	Other specified bacterial diseases

Cefiderocol

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection	Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Cefixime

Section	Indications
Watch group antibiotics ◦ Oral > Liquid: 100 mg per 5 mL powder for oral liquid ◦ Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)	**Second choix** Infectious gastroenteritis or colitis without specification of infectious agent co-prescrite avec azithromycin Gonococcal infection

Cefotaxime

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)	**Premier choix** Acute pyelonephritis (severe) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Bacterial pneumonia (Community-acquired pneumonia - severe) Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis co-prescrite avec amikacin Inflammatory or other diseases of prostate (severe) co-prescrite avec metronidazole Peritoneal abscess (mild-moderate) co-prescrite avec metronidazole Peritoneal abscess (severe) co-prescrite avec metronidazole Peritonitis (mild-moderate) co-prescrite avec metronidazole Peritonitis (severe) **Second choix** Acute pyelonephritis (mild to moderate) Sepsis without septic shock Bacterial infection of joint Inflammatory or other diseases of prostate (mild to moderate) Osteomyelitis or osteitis **Autres indications** Bacterial infection of unspecified site
Medicines for bacterial central nervous system infections ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)	**Premier choix** Bacterial meningitis

Ceftaroline

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection	Other specified bacterial diseases

Ceftazidime

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection	**Premier choix** Endophthalmitis **Autres indications** Pseudomonas aeruginosa resistant to other antibiotic

Ceftazidime + avibactam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection	Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Ceftolozane + tazobactam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 1 g + 0.5 g powder for injection	Carbapenem-resistant Pseudomonas aeruginosa

Ceftriaxone

Section	Indications
Watch group antibiotics	**Premier choix** Other specified pneumonia (Hospital-acquired pneumonia) Acute pyelonephritis (severe)

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Paratyphoid fever

Typhoid fever

Endophthalmitis

Bacterial pneumonia (Community-acquired pneumonia - severe)

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Bacterial meningitis

co-prescrite avec amikacin

Inflammatory or other diseases of prostate (severe)

co-prescrite avec azithromycin

Gonococcal infection

co-prescrite avec metronidazole

Necrotising fasciitis

co-prescrite avec metronidazole

Peritoneal abscess (mild-moderate)

co-prescrite avec metronidazole

Peritoneal abscess (severe)

co-prescrite avec metronidazole

Peritonitis (mild-moderate)

co-prescrite avec metronidazole

Peritonitis (severe)

Second choix

Acute pyelonephritis (mild to moderate)

Bacterial infection of joint

Sepsis without septic shock

Infectious gastroenteritis or colitis without specification of infectious agent

Inflammatory or other diseases of prostate (mild to moderate)

Osteomyelitis or osteitis

Autres indications

Bacterial infection of unspecified site

Medicines for bacterial central nervous system infections ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)	**Premier choix** Bacterial meningitis

Cefuroxime

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection	**Second choix** Other specified prophylactic measures

Cemiplimab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion	Therapeutic equivalent to pembrolizumab pour Adenocarcinoma of stomach Therapeutic equivalent to pembrolizumab pour Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of bronchus or lung

Certolizumab pegol

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
Medicines for juvenile joint diseases	Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
Dermatological medicines > Medicines affecting skin differentiation and proliferation	Therapeutic equivalent to adalimumab pour Psoriasis of unspecified type

Cetirizine

Section	Indications
Antiallergics and medicines used in anaphylaxis	Therapeutic equivalent to loratadine pour Allergic or hypersensitivity conditions of unspecified type

Chlorambucil

Section	Indications
Cytotoxic medicines ◦ Oral > Solid: 2 mg tablet	Chronic lymphocytic leukaemia or small lymphocytic lymphoma Unspecified malignant neoplasms of unspecified sites

Chloramphenicol

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate) ◦ Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection ◦ Oral > Liquid: 150 mg per 5 mL (as palmitate) ◦ Oral > Solid: 250 mg capsule	**Second choix** Bacterial meningitis **Autres indications** Bacterial infection of unspecified site
Medicines for bacterial central nervous system infections ◦ Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate) ◦ Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection	**Second choix** Bacterial meningitis

Chlorhexidine

Section	Indications
Medicines administered to the neonate [c] ◦ Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine) ◦ Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)	Omphalitis of newborn
Antiseptics ◦ Local > Topical > Solution: 5% (digluconate) for dilution	Chlorhexidine

Chlorine base compound

Section	Indications
Disinfectants ◦ Local > Topical > Powder: 0.1% available chlorine for solution ◦ Local > Topical > Liquid: 0.1% available chlorine for solution ◦ Local > Topical > Solid: 0.1% available chlorine for solution	Disinfectant, not elsewhere classified

Chloroquine

Section	Indications
Antimalarial medicines > Medicines for chemoprevention ◦ Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate) ◦ Oral > Solid: 150 mg tablet (as phosphate or sulfate)	Malaria due to Plasmodium falciparum Malaria due to Plasmodium ovale Malaria due to Plasmodium malariae Malaria due to Plasmodium vivax
Antimalarial medicines > Medicines for curative treatment ◦ Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate) ◦ Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate) ◦ Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate) ◦ Oral > Liquid: 50 mg per 5 mL (base) ◦ Oral > Solid > tablet: 150 mg (base)	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
Disease-modifying anti-rheumatic drugs (DMARDs) ◦ Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)	Rheumatoid arthritis
Antimalarial medicines > Medicines for chemoprophylaxis in travellers ◦ Oral > Liquid: 50 mg per 5 mL (base) ◦ Oral > Solid > tablet: 150 mg (base)	Malaria due to Plasmodium vivax

Chlorothiazide

Section	Indications
Antihypertensive medicines	Therapeutic equivalent to hydrochlorothiazide pour Essential hypertension
Medicines used in heart failure	Therapeutic equivalent to hydrochlorothiazide pour Heart failure

Chloroxylenol

Section	Indications
Disinfectants ◦ Local > Topical > Solution: 4.8%	Phenol disinfectant, not elsewhere classified

Chlorpromazine

Section	Indications
Medicines for psychotic disorders ◦ Oral > Liquid: 25 mg per 5 mL (hydrochloride) ◦ Oral > Solid: 100 mg (hydrochloride) ◦ Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride) ◦ Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride)	Therapeutic equivalent to haloperidol pour Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders

Chlortalidone

Section	Indications
Antihypertensive medicines	Therapeutic equivalent to hydrochlorothiazide pour Essential hypertension
Medicines used in heart failure	Therapeutic equivalent to hydrochlorothiazide pour Heart failure

Chlortetracycline

Section	Indications
Ophthalmological preparations > Anti-infective agents	Therapeutic equivalent to tetracycline pour Other specified conjunctivitis Therapeutic equivalent to tetracycline pour Infectious keratitis Therapeutic equivalent to tetracycline pour Infectious blepharitis Therapeutic equivalent to tetracycline pour Trachoma

Cholera vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against cholera alone

Ciclesonide

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to budesonide pour Asthma

Ciclopirox

Section	Indications
Dermatological medicines > Antifungal medicines ◦ Local > Topical > Solution: 80 mg per g (as hydroxypropyl chitosan)	Onychomycosis

Ciclosporin

Section	Indications
Immunomodulators for non-malignant disease ◦ Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection ◦ Oral > Liquid: 100 mg per mL ◦ Oral > Solid > capsule: 25 mg	Failure or rejection of transplanted organs or tissues

Cimetidine

Section	Indications
Antiulcer medicines ◦ Oral > Solid: 200 mg ◦ Parenteral > General injections > unspecified: 200 mg in 2 mL ampoule	Peptic ulcer, site unspecified Gastro-oesophageal reflux disease

Ciprofloxacin

Section	Indications
Ear, nose and throat medicines [c] ◦ Local > Otological > drops: 0.3% (as hydrochloride)	Infectious diseases of external ear
Watch group antibiotics ◦ Parenteral > General injections > IV: 2 mg per mL (as hyclate) ◦ Oral > Liquid: 250 mg per 5 mL (anhydrous) ◦ Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride) ◦ Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride) ◦ Oral > Solid: 250 mg (as hydrochloride)	**Premier choix** Acute pyelonephritis (mild to moderate) Paratyphoid fever Typhoid fever Infectious gastroenteritis or colitis without specification of infectious agent Neutropaenia (low-risk) Inflammatory or other diseases of prostate (mild to moderate) **Second choix** Cholera Cholera [children] co-prescrite avec metronidazole Peritoneal abscess (mild-moderate) co-prescrite avec metronidazole Peritonitis (mild-moderate) Bacterial infection of unspecified site

Cisplatin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 10 mg per 10 mL; 20 mg per 20 mL; 50 mg per 50 mL; 100 mg per 100 mL ◦ Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL ◦ Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection	Other specified gliomas of brain Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Malignant neoplasms of hypopharynx Malignant neoplasms of oropharynx Malignant neoplasms of nasopharynx Germ cell tumour of testis Osteosarcoma of bone or articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Malignant neoplasms of nasopharynx Other specified malignant neoplasms of bronchus or lung Unspecified malignant neoplasms of unspecified sites

Citalopram

Section	Indications
Medicines for anxiety disorders	Therapeutic equivalent to fluoxetine pour Generalised anxiety disorder

Cladribine

Section	Indications
Medicines for multiple sclerosis ◦ Oral > Solid > tablet: 10 mg	Multiple sclerosis
Cytotoxic medicines ◦ Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial	Langerhans cell histiocytosis

Clarithromycin

Section	Indications
Watch group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid ◦ Parenteral > General injections > unspecified: 500 mg in vial powder for injection ◦ Oral > Solid > dosage form: 500 mg; 250 mg ◦ Oral > Solid > dosage form: 500 mg	**Premier choix** co-prescrite avec cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe) **Second choix** Acute pharyngitis co-prescrite avec amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe) **Autres indications** Helicobacter pylori associated gastric ulcer

Clindamycin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate) ◦ Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride) ◦ Oral > Solid: 150 mg (as hydrochloride) ◦ Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride) ◦ Oral > Solid: 150 mg (as hydrochloride) capsule ◦ Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection	**Premier choix** Necrotising fasciitis **Second choix** Bacterial infection of joint Osteomyelitis or osteitis **Autres indications** Bacterial infection of unspecified site

Clofazimine

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dosage form: 100 mg; 50 mg	Multi-drug resistant Mycobacterium tuberculosis
Antileprosy medicines ◦ Oral > Solid > dosage form: 100 mg; 50 mg	Leprosy

Clomifene

Section	Indications
Ovulation inducers ◦ Oral > Solid: 50 mg (citrate)	Female infertility without specification whether primary or secondary

Clomipramine

Section	Indications
Medicines for obsessive compulsive disorders ◦ Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)	Obsessive-compulsive disorder

Clonazepam

Section	Indications
Medicines for central nervous system disorders ◦ Oral > Solid: 500 µg	Generalised myoclonic seizure

Clopidogrel

Section	Indications
Anti-platelet medicines ◦ Oral > Solid: 75 mg; 300 mg	Acute ischaemic heart disease Presence of coronary angioplasty implant or graft

Clotrimazole

Section	Indications
Antifungal medicines ◦ Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet	Vulvovaginal candidosis

Cloxacillin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid ◦ Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection ◦ Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt) ◦ Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid ◦ Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule ◦ Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection	**Premier choix** Bacterial infection of joint Osteomyelitis or osteitis Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Sepsis without septic shock **Autres indications** Bacterial infection of unspecified site

Clozapine

Section	Indications
Medicines for psychotic disorders ◦ Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg	Schizophrenia or other primary psychotic disorders

Coagulation factor IX complex

Section	Indications
Coagulation factors	Therapeutic equivalent to coagulation factor IX, plasma-derived pour Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to coagulation factor IX, plasma-derived pour Haemophilia B

Coagulation factor IX, plasma-derived

Section	Indications
Coagulation factors ◦ Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection	Coagulation defects, purpura or other haemorrhagic or related conditions Haemophilia B

Coagulation factor IX, recombinant

Section	Indications
Coagulation factors ◦ Parenteral > General injections > IV: 250 IU per mL in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection	Haemophilia B

Coagulation factor VIII, plasma-derived

Section	Indications
Coagulation factors ◦ Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection	Haemophilia A

Coagulation factor VIII, recombinant

Section	Indications
Coagulation factors ◦ Parenteral > General injections > IV: 250 IU in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection	Haemophilia A

Coal tar

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Local > Topical > Solution: 5%	Psoriasis of unspecified type

Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Cobimetinib

Section	Indications
Targeted therapies	Therapeutic equivalent to trametinib pour Other specified melanoma of skin

Codeine

Section	Indications
Antitussives ◦ Oral > Solid: 10 mg tablet (codeine phosphate)	Cough
Opioid analgesics ◦ Oral > Solid: 30 mg tablet (codeine phosphate)	Pain
Medicines for diarrhoea ◦ Oral > Solid: 30 mg tablet (codeine phosphate)	Diarrhoea

Colchicine

Section	Indications
Medicines used to treat gout ◦ Oral > Solid: 0.5 mg	Gout

Colecalciferol

Section	Indications
Vitamins and minerals ◦ Oral > Liquid: 400 IU per mL ◦ Oral > Solid: 400 IU; 1000 IU	Calcium deficiency Vitamin D deficiency Therapeutic equivalent to ergocalciferol pour Calcium deficiency Therapeutic equivalent to ergocalciferol pour Vitamin D deficiency

Colistin (injection)

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) ◦ Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)	Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Compound sodium lactate solution

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Parenteral ◦ Parenteral > General injections > IV: injectable solution	Hypovolaemic shock Other specified disorders of fluid, electrolyte or acid-base balance

Condoms

Section	Indications
Barrier methods ◦ -	Contact with health services for contraceptive management

Copper-containing intrauterine device

Section	Indications
Intrauterine devices ◦ -	Contact with health services for insertion of contraceptive device

Crizotinib

Section	Indications
Targeted therapies ◦ Oral > Solid > capsule: 200 mg; 250 mg ◦ Oral > Solid: 200 mg; 250 mg	Anaplastic large cell lymphoma, ALK-positive Other specified malignant neoplasms of bronchus or lung

Cryoprecipitate (native)

Section	Indications
Blood and blood components	Therapeutic equivalent to cryoprecipitate (pathogen-reduced) pour Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to cryoprecipitate (pathogen-reduced) pour Obstetric haemorrhage Therapeutic equivalent to cryoprecipitate (pathogen-reduced) pour Haemophilia A Therapeutic equivalent to cryoprecipitate (pathogen-reduced) pour Von Willebrand disease

Cryoprecipitate (pathogen-reduced)

Section	Indications
Blood and blood components ◦ Injection: frozen liquid in bag or lyophilized powder in vial containing: ◦ > 50 IU Factor VIII ◦ > 100 IU vWF ◦ > 140 mg clottable fibrinogen per unit	Coagulation defects, purpura or other haemorrhagic or related conditions Obstetric haemorrhage Haemophilia A Von Willebrand disease

Cyanocobalamin

Section	Indications
Antianaemia medicines ◦ .	Anaemias or other erythrocyte disorders

Cyclizine

Section	Indications
Medicines for other common symptoms in palliative care ◦ Parenteral > General injections > unspecified: 50 mg per mL (lactate) ◦ Oral > Solid > tablet: 50 mg (hydrochloride)	Palliative care

Cyclopentolate

Section	Indications
Diagnostic agents > Ophthalmic medicines	Therapeutic equivalent to tropicamide pour Cycloplegic drug
Ophthalmological preparations > Mydriatics	Therapeutic equivalent to atropine pour Anterior uveitis

Cyclophosphamide

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection ◦ Oral > Solid > dosage form: 25 mg; 50 mg ◦ Oral > Solid: 25 mg tablet ◦ Parenteral > General injections > unspecified: 500 mg in vial powder for injection	Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Other specified gliomas of brain Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Rhabdomyosarcoma primary site Malignant neoplasms of breast Other specified malignant neoplasms of breast Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma Malignant trophoblastic neoplasms of placenta Follicular lymphoma Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis

Cycloserine

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dosage form: 250 mg; 125 mg	Multi-drug resistant Mycobacterium tuberculosis

Cytarabine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial ◦ Parenteral > General injections > unspecified: 100 mg in vial powder for injection	Acute myeloid leukaemia with recurrent genetic abnormalities Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis Unspecified malignant neoplasms of unspecified sites

Cytisine (cytisinicline)

Section	Indications
Medicines for nicotine use disorders ◦ Oral > Solid > tablet: 1.5 mg	Nicotine dependence

Dabigatran

Section	Indications
Medicines affecting coagulation ◦ Oral > Solid: 110 mg; 150 mg	Other specified atrial fibrillation Venous thromboembolism

Dabrafenib

Section	Indications
Targeted therapies ◦ Oral > Solid: 50 mg; 75 mg	Other specified melanoma of skin

Dacarbazine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection	Hodgkin lymphoma

Daclatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations ◦ Oral > Solid > tablet: 30 mg (as dihydrochloride); 60 mg (as dihydrochloride)	Chronic hepatitis C

Daclatasvir + sofosbuvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations ◦ Oral > Solid > tablet: 60 mg (as dihydrochloride) + 400 mg	Chronic hepatitis C

Dactinomycin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 500 µg in vial powder for injection	Rhabdomyosarcoma primary site Unspecified malignant neoplasms of unspecified sites Malignant trophoblastic neoplasms of placenta Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis

Dalteparin

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to enoxaparin pour Acute ischaemic heart disease Therapeutic equivalent to enoxaparin pour Venous thromboembolism

Dapagliflozin

Section	Indications
Hypoglycaemic agents	Therapeutic equivalent to empagliflozin pour Type 2 diabetes mellitus

Dapsone

Section	Indications
Antileprosy medicines ◦ Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet	Leprosy

Daptomycin

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection	Other specified bacterial diseases

Daratumumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL	Plasma cell myeloma

Darbepoetin alfa

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
Supportive medicines	Therapeutic equivalent to erythropoiesis-stimulating agents pour Drug-induced aplastic anaemia

Darunavir

Section	Indications
Antiretrovirals > Protease inhibitors ◦ Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Dasabuvir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations ◦ Oral > Solid: 250 mg tablet	Chronic hepatitis C

Dasatinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet	Chronic myelogenous leukaemia, BCR-ABL1-positive

Daunorubicin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)	Acute myeloid leukaemia with recurrent genetic abnormalities Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia

Deferasirox

Section	Indications
Medicines for haemoglobinopathies ◦ Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg ◦ Oral > Solid > tablet: 90 mg; 180 mg; 360 mg	Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias

Deferiprone

Section	Indications
Medicines for haemoglobinopathies	Therapeutic equivalent to deferasirox pour Other specified sickle cell disorders or other haemoglobinopathies Therapeutic equivalent to deferasirox pour Thalassaemias

Deferoxamine

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)	Harmful effects of drugs, medicaments or biological substances, not elsewhere classified
Medicines for haemoglobinopathies ◦ Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)	Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias

Delafloxacin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 300 mg lyophilized powder for injection ◦ Oral > Solid: 450 mg	Methicillin resistant Staphylococcus aureus

Delamanid

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 25 mg ◦ Oral > Solid > tablet: 50 mg	Multi-drug resistant Mycobacterium tuberculosis

Dengue vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against certain single viral diseases

Desmopressin

Section	Indications
Medicines affecting coagulation ◦ Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate) ◦ Local > Nasal > Spray: 150 µg per actuation (acetate)	Haemophilia A Von Willebrand disease

Dexamethasone

Section	Indications
Other medicines administered to the mother ◦ Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))	Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy
Hormones and antihormones ◦ Oral > Liquid: 2 mg per 5 mL ◦ Oral > Solid: 2 mg; 4 mg ◦ Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt) ◦ Oral > Liquid: 2 mg per 5 mL (as sodium phosphate) ◦ Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base) ◦ Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base) ◦ Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base ◦ Oral > Solid > tablet: 4 mg (as dexamethasone base)	Anaplastic large cell lymphoma, ALK-negative Lymphoid leukaemia, not elsewhere classified Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-positive
Antiallergics and medicines used in anaphylaxis ◦ Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate); 2 mg per 5 mL (as sodium phosphate) ◦ Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base) ◦ Oral > Solid > tablet: 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base); 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)	Allergic or hypersensitivity conditions of unspecified type

Medicines for other common symptoms in palliative care ◦ Oral > Liquid: 2 mg per 5 mL (as sodium phosphate); 0.5 mg per 5 mL (as sodium phosphate) ◦ Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (dexamethasone phosphate (as sodium phosphate) equialent to 3.3 mg dexamethasone base) ◦ Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base); 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base)	Palliative care
Antiemetic medicines ◦ Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate); 2 mg per 5 mL (as sodium phosphate) ◦ Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base) ◦ Oral > Solid > tablet: 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base); 4 mg (as dexamethasone base); 2 mg (as dexamethasone base)	Nausea or vomiting

Dextran 40

Section	Indications
Plasma substitutes ◦ .	Hypovolaemia

Dextran 70

Section	Indications
Plasma substitutes ◦ Parenteral > General injections > IV: 6% injectable solution	Hypovolaemia

Diaphragms

Section	Indications
Barrier methods ◦ -	Contact with health services for contraceptive management

Diazepam

Section	Indications
Antiseizure medicines ◦ Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system ◦ Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube	Therapeutic equivalent to lorazepam pour Status epilepticus Status epilepticus
Medicines for other common symptoms in palliative care ◦ Oral > Liquid: 2 mg per 5 mL ◦ Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system ◦ Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube ◦ Parenteral > General injections > unspecified: 5 mg per mL ◦ Oral > Solid > tablet: 5 mg (scored); 10 mg (scored); 2 mg (scored)	Palliative care
Medicines for anxiety disorders ◦ Oral > Solid: 5 mg (scored); 2 mg (scored)	Anxiety

Diazoxide

Section	Indications
Medicines for hypoglycaemia ◦ Oral > Liquid: 50 mg per mL ◦ Oral > Solid: 50 mg	Persistent hyperinsulinaemic hypoglycaemia of infancy

Dicloxacillin

Section	Indications
Access group antibiotics	**Premier choix** Therapeutic equivalent to cloxacillin pour Bacterial infection of joint Therapeutic equivalent to cloxacillin pour Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin pour Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Therapeutic equivalent to cloxacillin pour Sepsis without septic shock

Didanosine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution ◦ Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Diethylcarbamazine

Section	Indications
Antifilarials ◦ Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)	Lymphatic filariasis

Digitoxin

Section	Indications
Medicines used in heart failure ◦ Parenteral > General injections > IV: 0.2 mg in 1 mL ampoule ◦ Oral > Solid: 50 µg; 100 µg	Heart failure

Digoxin

Section	Indications
Antiarrhythmic medicines ◦ Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule ◦ Oral > Liquid: 50 µg per mL ◦ Oral > Solid: 62.5 µg; 250 µg	Cardiac arrhythmia
Medicines used in heart failure ◦ Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule; 100 µg per mL in 1 mL ampoule ◦ Oral > Liquid: 50 µg per mL ◦ Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg	Heart failure

Dihydroartemisinin + piperaquine

Section	Indications
Antimalarial medicines > Medicines for curative treatment ◦ Oral > Solid > dispersible tablet: 20 mg + 160 mg (phosphate); 40 mg + 320 mg (phosphate) ◦ Oral > Solid > tablet: 40 mg + 320 mg (phosphate); 20 mg + 160 mg (phosphate); 60 mg + 480 (phosphate); 80 mg + 640 mg (phosphate)	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Dihydroergocryptine mesylate

Section	Indications
Medicines for central nervous system disorders ◦ Oral > Solid:	Parkinson disease

Diloxanide

Section	Indications
Antiamoebic and antigiardiasis medicines ◦ Oral > Solid: 500 mg (furoate)	Amoebiasis

Dimercaprol

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule; 100 mg per mL in 3 mL ampoule	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Dinoprostone (prostaglandin E2)

Section	Indications
Medicines administered to the neonate [c] ◦ Parenteral > General injections > IV: 1 mg per mL	Therapeutic equivalent to alprostadil (prostaglandin E1) pour Other specified congenital anomaly of great arteries including arterial duct Other specified congenital anomaly of great arteries including arterial duct

Diphtheria antitoxin

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial	Need for immunization against diphtheria alone

Diphtheria vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against diphtheria alone

Diphtheria-pertussis-tetanus vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against diphtheria-tetanus-pertussis, combined

Diphtheria-tetanus vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against combinations of infectious diseases

Docetaxel

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL	Malignant neoplasms of breast Other specified malignant neoplasms of breast Unspecified malignant neoplasms of unspecified sites Malignant neoplasms of prostate

Docusate sodium

Section	Indications
Medicines for other common symptoms in palliative care ◦ Oral > Liquid: 50 mg per 5 mL; 12.5 mg per 5 mL ◦ Oral > Solid > capsule: 100 mg	Palliative care

Dolasetron

Section	Indications
Medicines for other common symptoms in palliative care	Therapeutic equivalent to ondansetron pour Palliative care
Antiemetic medicines	Therapeutic equivalent to ondansetron pour Nausea or vomiting

Dolutegravir

Section	Indications
Antiretrovirals > Integrase inhibitors ◦ Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Dolutegravir + lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Donepezil

Section	Indications
Medicines for neurological disorders ◦ Oral > Liquid: 1 mg per mL (hydrochloride) ◦ Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 5 mg (hydrochloride) (orodispersible); 10 mg (hydrochloride) (orodispersible)	Dementia due to Alzheimer disease

Dopamine

Section	Indications
Medicines used in heart failure ◦ Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)	Cardiogenic shock Heart failure

Dostarlimab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion	Other specified malignant neoplasms of corpus uteri

Doxorubicin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride) ◦ Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)	Diffuse large B-cell lymphoma, not otherwise specified Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Rhabdomyosarcoma primary site Osteosarcoma of bone or articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site Malignant neoplasms of breast Other specified malignant neoplasms of breast Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma Follicular lymphoma Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis

Doxorubicin (as pegylated liposomal)

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)	Kaposi sarcoma of unspecified primary site

Doxycycline

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium) ◦ Parenteral > General injections > unspecified: 100 mg in vial powder for injection ◦ Oral > Solid > dispersible tablet: 100 mg (as monohydrate) ◦ Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate) ◦ Oral > Solid > dosage form: 100 mg (as hyclate) ◦ Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous) ◦ Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)	**Premier choix** Cholera Chlamydia trachomatis **Second choix** Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Cholera [children] Chronic obstructive pulmonary disease with acute exacerbation **Autres indications** Bacterial infection of unspecified site
Antimalarial medicines > Medicines for chemoprophylaxis in travellers ◦ Oral > Liquid: 50 mg per 5 mL (calcium); 25 mg per 5 mL (monohydrate) powder for oral liquid ◦ Oral > Solid > dispersible tablet: 100 mg (as monohydrate) ◦ Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)	Malaria due to Plasmodium falciparum
Antimalarial medicines > Medicines for curative treatment ◦ Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)	Malaria due to Plasmodium falciparum
Antimalarial medicines > Medicines for chemoprevention ◦ Oral > Solid: 100 mg (hydrochloride or hyclate)	Malaria due to Plasmodium falciparum

Dulaglutide

Section	Indications
Hypoglycaemic agents	Therapeutic equivalent to semaglutide pour Obesity Therapeutic equivalent to semaglutide pour Type 2 diabetes mellitus

Durvalumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion	Hepatocellular carcinoma of liver Malignant neoplasms of biliary tract, distal bile duct Malignant neoplasm of intrahepatic bile ducts Malignant neoplasms of gallbladder Malignant neoplasms of proximal biliary tract, cystic duct Other specified malignant neoplasms of bronchus or lung

Edoxaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation Therapeutic equivalent to dabigatran pour Venous thromboembolism

Efavirenz

Section	Indications
Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors ◦ Oral > Solid: 600 mg tablet	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Efavirenz + emtricitabine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Efavirenz + lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified Therapeutic equivalent to efavirenz + emtricitabine + tenofovir pour Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Eflornithine

Section	Indications
Medicines for the treatment of 2nd stage African trypanosomiasis ◦ Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)	Gambiense trypanosomiasis

Elbasvir + grazoprevir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations ◦ Oral > Solid: 50 mg + 100 mg	Chronic hepatitis C

Eletriptan

Section	Indications
Medicines for acute migraine attacks ◦ Oral > Solid > tablet: 40 mg	Therapeutic equivalent to sumatriptan pour Migraine

Elexacaftor + tezacaftor + ivacaftor

Section	Indications
Medicines for cystic fibrosis ◦ Oral > Solid > tablet: 50 mg + 25 mg + 37.5 mg; 100 mg + 50 mg + 75 mg ◦ Oral > Solid > granules: 80 mg + 40 mg + 60 mg in sachet; 100 mg + 50 mg + 75 mg in sachet	Cystic fibrosis

Emicizumab

Section	Indications
Medicines affecting coagulation ◦ Parenteral > General injections > SC: 12 mg per 0.4 mL in vial; 30 mg per mL in mL vial; 60 mg per 0.4 mL in vial; 105 mg per 0.7 mL in vial; 150 mg per mL in vial; 300 mg per 2 mL in vial	Haemophilia A

Empagliflozin

Section	Indications
Hypoglycaemic agents ◦ Oral > Solid: 10 mg; 25 mg	Type 2 diabetes mellitus

Emtricitabine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Liquid: 10 mg per mL ◦ Oral > Solid: 200 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir alafenamide

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 200 mg + 25 mg + 25 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Emtricitabine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Contact with or exposure to human immunodeficiency virus Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Emtricitabine + tenofovir alafenamide

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Enalapril

Section	Indications
Antihypertensive medicines ◦ Oral > Liquid: 1 mg per mL (as hydrogen maleate) ◦ Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)	Essential hypertension
Medicines used in heart failure ◦ Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)	Heart failure

Encorafenib

Section	Indications
Targeted therapies	Therapeutic equivalent to dabrafenib pour Other specified melanoma of skin

Enoxaparin

Section	Indications
Medicines affecting coagulation ◦ Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule	Acute ischaemic heart disease Venous thromboembolism

Entecavir

Section	Indications
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Liquid: 0.05 mg per mL ◦ Oral > Solid: 0.5 mg; 1 mg	Chronic hepatitis B

Enzalutamide

Section	Indications
Hormones and antihormones ◦ Oral > Solid: 40 mg	Therapeutic equivalent to abiraterone pour Malignant neoplasms of prostate Malignant neoplasms of prostate

Ephedrine

Section	Indications
Local anaesthetics ◦ Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)	Cardiac complications of anaesthesia during labour or delivery

Epinephrine

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease ◦ Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)	Chronic obstructive pulmonary disease Asthma
Antiallergics and medicines used in anaphylaxis ◦ Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)	Anaphylaxis
Antiarrhythmic medicines ◦ Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)	Cardiac arrest
Ophthalmological preparations > Mydriatics ◦ Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)	Primary open-angle glaucoma

Epoetin alfa

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
Supportive medicines	Therapeutic equivalent to erythropoiesis-stimulating agents pour Drug-induced aplastic anaemia

Epoetin beta

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
Supportive medicines	Therapeutic equivalent to erythropoiesis-stimulating agents pour Drug-induced aplastic anaemia

Epoetin theta

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease

Eptinezumab

Section	Indications
Medicines for migraine prophylaxis	Therapeutic equivalent to fremanezumab pour Chronic migraine

Equine rabies immunoglobulin

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial	Rabies

Eravacycline

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 50 mg lyophilized powder for injection	Other carbapenem resistant Enterobacterales

Erenumab

Section	Indications
Medicines for migraine prophylaxis	Therapeutic equivalent to fremanezumab pour Chronic migraine

Ergocalciferol

Section	Indications
Vitamins and minerals ◦ Oral > Liquid: 250 µg per mL (10 000 IU per mL) ◦ Oral > Solid: 1.25 mg (50 000 IU)	Therapeutic equivalent to colecalciferol pour Calcium deficiency Therapeutic equivalent to colecalciferol pour Vitamin D deficiency Calcium deficiency Vitamin D deficiency

Ergometrine

Section	Indications
Uterotonics ◦ Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)	Postpartum haemorrhage

Erlotinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 100 mg; 150 mg	Other specified malignant neoplasms of bronchus or lung

Erythromycin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate) ◦ Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate) ◦ Oral > Solid: 250 mg (as stearate or ethylsuccinate)	**Second choix** Therapeutic equivalent to clarithromycin pour Acute pharyngitis **Autres indications** Bacterial infection of unspecified site
Ophthalmological preparations > Anti-infective agents ◦ Local > Ophthalmological > Ointment: 0.5%	Chlamydial conjunctivitis Gonococcal infection of eye

Erythropoiesis-stimulating agents

Section	Indications
Antianaemia medicines ◦ Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe	Anaemia due to chronic disease
Supportive medicines ◦ Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)	Drug-induced aplastic anaemia

Escitalopram

Section	Indications
Medicines for anxiety disorders	Therapeutic equivalent to fluoxetine pour Generalised anxiety disorder

Estradiol

Section	Indications
Estrogens ◦ Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg	Hypopituitarism Gonadotropin deficiency Turner syndrome

Estradiol cypionate + medroxyprogesterone acetate

Section	Indications
Injectable hormonal contraceptives ◦ Parenteral > General injections > IM: 5 mg + 25 mg	Contact with health services for reasons associated with reproduction

Etanercept

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
Medicines for juvenile joint diseases	Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
Dermatological medicines > Medicines affecting skin differentiation and proliferation	Therapeutic equivalent to adalimumab pour Psoriasis of unspecified type

Ethambutol

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL ◦ Oral > Solid > dispersible tablet: 100 mg ◦ Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)	Other specified tuberculosis Tuberculosis

Ethambutol + isoniazid

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 400 mg + 150 mg tablet	Tuberculosis

Ethambutol + isoniazid + pyrazinamide + rifampicin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet	Tuberculosis

Ethambutol + isoniazid + rifampicin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 275 mg + 75 mg + 150 mg tablet	Tuberculosis

Ethanol

Section	Indications
Antiseptics ◦ Local > Topical > Solution: 70% (denatured)	Denatured alcohol

Ether

Section	Indications
General anaesthetics and oxygen > Inhalational medicines ◦ Respiratory > Inhalation > solution:	Anaesthetics and therapeutic gases

Ethinylestradiol + etonogestrel

Section	Indications
Intravaginal contraceptives ◦ Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg	Contact with health services for contraceptive management

Ethinylestradiol + levonorgestrel

Section	Indications
Oral hormonal contraceptives ◦ Oral > Solid: 50 µg + 250 µg [4] ◦ Oral > Solid: 30 µg + 150 µg	Contact with health services for postcoital contraception Contact with health services for contraceptive management

Ethinylestradiol + norethisterone

Section	Indications
Oral hormonal contraceptives ◦ Oral > Solid: 35 µg + 1 mg	Contact with health services for contraceptive management

Ethionamide

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 125 mg ◦ Oral > Solid > tablet: 250 mg	Tuberculous meningitis Multi-drug resistant Mycobacterium tuberculosis

Ethosuximide

Section	Indications
Antiseizure medicines ◦ Oral > Liquid: 250 mg per 5 mL ◦ Oral > Solid: 250 mg	Absence seizures, typical

Etonogestrel-releasing implant

Section	Indications
Implantable contraceptives ◦ Implant > Subdermal: 68 mg single rod	Contact with health services for insertion of contraceptive device

Etoposide

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate) ◦ Oral > Solid: 100 mg capsule; 50 mg capsule ◦ Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule ◦ Oral > Solid: 100 mg capsule	Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Germ cell tumour of testis Osteosarcoma of bone or articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma Malignant trophoblastic neoplasms of placenta Retinoblastoma Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis

Everolimus

Section	Indications
Targeted therapies ◦ Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg ◦ Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg	Other specified gliomas of brain

Exenatide

Section	Indications
Hypoglycaemic agents	Therapeutic equivalent to semaglutide pour Obesity

Fentanyl

Section	Indications
Opioid analgesics ◦ Oral > Solid: 100 to 800 µg sub-lingual tablet (as citrate); 200 to 1600 µg lozenge (as citrate) ◦ Oral > Other: 200 to 1200 µg buccal film (as citrate) ◦ Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour	Other specified chronic cancer related pain Chronic cancer pain

Ferrous salt

Section	Indications
Antianaemia medicines ◦ Oral > Liquid: 25 mg per mL elemental iron; 9 mg per mL elemental iron ◦ Oral > Solid > tablet: 60 to 65 mg elemental iron	Iron deficiency anaemia

Ferrous salt + folic acid

Section	Indications
Antianaemia medicines ◦ Oral > Solid: 60 mg iron + 2.8 mg ◦ Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg	Iron deficiency anaemia Iron deficiency anaemia Spina bifida Clefts of lip, alveolus or palate Anencephaly or similar anomalies

Fexinidazole

Section	Indications
Medicines for the treatment of 1st stage African trypanosomiasis ◦ Oral > Solid > tablet: 600 mg ◦ Oral > Solid: 600 mg	Rhodesiense trypanosomiasis Gambiense trypanosomiasis
Medicines for the treatment of 2nd stage African trypanosomiasis ◦ Oral > Solid > tablet: 600 mg ◦ Oral > Solid: 600 mg	Rhodesiense trypanosomiasis Gambiense trypanosomiasis

Fexofenadine

Section	Indications
Antiallergics and medicines used in anaphylaxis	Therapeutic equivalent to loratadine pour Allergic or hypersensitivity conditions of unspecified type

Fifth generation cephalosporins

Section	Indications
Reserve group antibiotics ◦ .	Other specified bacterial diseases

Filgrastim

Section	Indications
Immunomodulators ◦ Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial	Acquired neutropaenia

Fingolimod

Section	Indications
Immunomodulators for non-malignant disease ◦ Oral > Solid: 0.25 mg; 0.5 mg	Relapsing-remitting multiple sclerosis

Flomoxef

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection	Other specified other antibiotic resistant Enterobacterales

Flucloxacillin

Section	Indications
Access group antibiotics	**Premier choix** Therapeutic equivalent to cloxacillin pour Bacterial infection of joint Therapeutic equivalent to cloxacillin pour Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin pour Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Therapeutic equivalent to cloxacillin pour Sepsis without septic shock

Fluconazole

Section	Indications
Antifungal medicines ◦ Parenteral > General injections > IV: 2 mg per mL in vial ◦ Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid ◦ Oral > Solid > capsule: 50 mg	Cryptococcosis Candidosis

Flucytosine

Section	Indications
Antifungal medicines ◦ Parenteral > General injections > IV: 2.5 g per 250 mL infusion ◦ Oral > Solid: 250 mg capsule	Cryptococcosis

Fludarabine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection ◦ Oral > Solid: 10 mg tablet (fludarabine phosphate)	Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Fludrocortisone

Section	Indications
Adrenal hormones and synthetic substitutes ◦ Oral > Liquid: 100 µg per mL ◦ Oral > Solid > tablet: 100 µg (acetate)	Adrenocortical insufficiency

Fluorescein

Section	Indications
Diagnostic agents > Ophthalmic medicines ◦ Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)	Fluorescein

Fluoride

Section	Indications
Dental medicines and preparations ◦ Local > Dental > Gel: 2500 to 12500 ppm fluoride (any type) ◦ Local > Dental > Toothpaste, cream or gel: 1000 to 1500 ppm fluoride (any type) ◦ Local > Dental > Mouthrinse: 230 to 900 ppm fluoride (any type) ◦ Local > Dental > Varnish: 22500 ppm fluoride (any type)	Dental caries

Fluorouracil

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Local > Topical > Ointment: 5%	Plantar warts
Cytotoxic medicines ◦ Parenteral > General injections > IV: 50 mg per mL in vial ◦ Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule	Malignant neoplasms of nasopharynx Malignant neoplasms of rectum Malignant neoplasm metastasis in large intestine Malignant neoplasms of breast Malignant neoplasms of colon Unspecified malignant neoplasms of unspecified sites

Fluoxetine

Section	Indications
Medicines for other common symptoms in palliative care ◦ Oral > Solid: 20 mg (as hydrochloride)	Palliative care
Medicines for depressive disorders ◦ Oral > Solid: 20 mg (as hydrochloride)	Depressive disorders
Medicines for anxiety disorders ◦ Oral > Solid: 20 mg (as hydrochloride)	Generalised anxiety disorder Social anxiety disorder Panic disorder
Medicines for obsessive compulsive disorders ◦ Oral > Solid: 20 mg (as hydrochloride)	Obsessive-compulsive disorder

Fluphenazine

Section	Indications
Medicines for psychotic disorders ◦ Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)	Schizophrenia or other primary psychotic disorders

Flutamide

Section	Indications
Hormones and antihormones	Therapeutic equivalent to bicalutamide pour Malignant neoplasms of prostate

Fluticasone

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to budesonide pour Asthma

Fluticasone + formoterol

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to budesonide + formoterol pour Asthma

Fluticasone furoate + vilanterol

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to budesonide + formoterol pour Asthma

Fluvastatin

Section	Indications
Lipid-lowering agents	Therapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis

Fluvoxamine

Section	Indications
Medicines for anxiety disorders	Therapeutic equivalent to fluoxetine pour Generalised anxiety disorder

Folic acid

Section	Indications
Antianaemia medicines ◦ Oral > Solid: 400 µg ◦ Oral > Liquid: 1 mg per mL ◦ Oral > Solid: 1 mg tablet; 5 mg tablet	Cephalocele Anencephaly or similar anomalies Spina bifida Folate deficiency anaemia

Fomepizole

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule or vial (sulfate); 1 g per mL in 1.5 mL ampoule or vial (base)	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Fosfomycin (injection)

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection	Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales

Fourth generation cephalosporins

Section	Indications
Watch group antibiotics ◦ .	Other specified bacterial diseases

Fremanezumab

Section	Indications
Medicines for migraine prophylaxis ◦ Parenteral > General injections > SC: 225 mg per 1.5 mL in pre-filled syringe	Chronic migraine

Fresh-frozen plasma

Section	Indications
Blood and blood components ◦ Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

Fulvestrant

Section	Indications
Hormones and antihormones ◦ Parenteral > General injections > IV: 250 mg per 5 mL	Malignant neoplasms of breast

Furosemide

Section	Indications
Diuretics ◦ Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule ◦ Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL ◦ Oral > Solid > tablet: 40 mg; 20 mg	Anuria or oliguria Oedema
Medicines used in heart failure ◦ Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule ◦ Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL ◦ Oral > Solid > tablet: 40 mg; 20 mg	Heart failure

Gabapentin

Section	Indications
Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) ◦ Oral > Solid: 100 mg; 200 mg; 300 mg; 400 mg; 600 mg; 800 mg	Neuropathic pain

Galcanezumab

Section	Indications
Medicines for migraine prophylaxis	Therapeutic equivalent to fremanezumab pour Chronic migraine

Gallamine

Section	Indications
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors ◦ Parenteral > General injections > IV: 40 mg per mL in 2 mL ampoule (gallamine triethiodide)	Muscle relaxants

Gatifloxacin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 200 mg; 400 mg	Multi-drug resistant Mycobacterium tuberculosis

Gefitinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib pour Other specified malignant neoplasms of bronchus or lung

Gemcitabine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection	Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung

Gentamicin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)	**Premier choix** Neonatal meningitis Sepsis without septic shock Sepsis without septic shock Sepsis without septic shock co-prescrite avec amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicillin Peritoneal abscess (mild-moderate) co-prescrite avec ampicillin Peritoneal abscess (severe) co-prescrite avec ampicillin Peritonitis (mild-moderate) co-prescrite avec ampicillin Peritonitis (severe) co-prescrite avec benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] **Second choix** Other specified prophylactic measures Gonococcal infection **Autres indications** Bacterial infection of unspecified site

Section	Indications
Ophthalmological preparations > Anti-infective agents ◦ Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)	Other specified conjunctivitis Infectious blepharitis
Medicines for bacterial central nervous system infections ◦ Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)	**Premier choix** Neonatal meningitis

Glass ionomer cement

Section	Indications
Dental medicines and preparations ◦ Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid	Dental caries

Glatiramer acetate

Section	Indications
Medicines for multiple sclerosis ◦ Parenteral > General injections > SC: 20 mg per mL; 40 mg per mL ◦ Parenteral > General injections > SC: 20 mg per mL in pre-filled syringe; 40 mg per mL in pre-filled syringe	Relapsing-remitting multiple sclerosis Multiple sclerosis

Glecaprevir + pibrentasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations ◦ Oral > Solid: 50 mg + 20 mg granules ◦ Oral > Solid > tablet: 100 mg + 40 mg	Chronic hepatitis C

Glibenclamide

Section	Indications
Hypoglycaemic agents ◦ Oral > Solid: 5 mg; 2.5 mg	Type 2 diabetes mellitus

Gliclazide

Section	Indications
Hypoglycaemic agents ◦ Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release	Type 2 diabetes mellitus

Glucagon

Section	Indications
Medicines for hypoglycaemia ◦ Parenteral > General injections > unspecified: 1 mg per mL as powder and diluent	Hypoglycaemia in the context of diabetes

Glucose

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Parenteral ◦ Parenteral > General injections > IV: 50% hypertonic ◦ Parenteral > General injections > IV: 5% isotonic; 10% hypertonic	Hypoglycaemia without associated diabetes Other specified disorders of fluid, electrolyte or acid-base balance

Glucose + sodium chloride

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Parenteral ◦ Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)	Other specified disorders of fluid, electrolyte or acid-base balance

Glutaral

Section	Indications
Disinfectants ◦ Local > Topical > Solution: 2%	Glutaral nonmedicinal

Glycerol

Section	Indications
Dermatological medicines > Moisturizers ◦ Local > Topical > Cream: 15 to 20%	Atopic eczema

Glyceryl trinitrate

Section	Indications
Antianginal medicines ◦ Oral > Solid: 500 µg sublingual tablet	Angina pectoris

Glycopyrronium

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to tiotropium bromide pour Chronic obstructive pulmonary disease

Golimumab

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
Medicines for juvenile joint diseases	Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis

Goserelin

Section	Indications
Hormones and antihormones	Therapeutic equivalent to leuprorelin pour Malignant neoplasms of breast Therapeutic equivalent to leuprorelin pour Malignant neoplasms of prostate

Granisetron

Section	Indications
Medicines for other common symptoms in palliative care	Therapeutic equivalent to ondansetron pour Palliative care
Antiemetic medicines	Therapeutic equivalent to ondansetron pour Nausea or vomiting

Griseofulvin

Section	Indications
Antifungal medicines ◦ Oral > Liquid: 125 mg per 5 mL ◦ Oral > Solid: 125 mg; 250 mg	Dermatophytosis

Haemophilus influenzae type b vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against single bacterial diseases

Haloperidol

Section	Indications
Medicines for other common symptoms in palliative care ◦ Oral > Liquid: 2 mg per mL ◦ Oral > Solid: 0.5 mg; 2 mg; 5 mg ◦ Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule	Palliative care
Medicines for psychotic disorders ◦ Parenteral > General injections > IM: 5 mg per mL in ampoule ◦ Oral > Solid: 2 mg; 5 mg	Schizophrenia or other primary psychotic disorders

Haloperidol decanoate

Section	Indications
Medicines for psychotic disorders	Therapeutic equivalent to fluphenazine pour Schizophrenia or other primary psychotic disorders

Halothane

Section	Indications
General anaesthetics and oxygen > Inhalational medicines ◦ Respiratory > Inhalation > liquid:	Anaesthetics and therapeutic gases

Heparin sodium

Section	Indications
Medicines affecting coagulation ◦ Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule or vial; 20000 IU per mL in 1 mL ampoule or vial; 5000 IU per mL in 1 mL ampoule or vial	Acute ischaemic heart disease Unstable angina Venous thromboembolism

Hepatitis A vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against viral hepatitis

Hepatitis B vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against viral hepatitis

Hepatitis E vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against viral hepatitis

Homatropine

Section	Indications
Ophthalmological preparations > Mydriatics ◦ Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)	Anterior uveitis Therapeutic equivalent to atropine pour Anterior uveitis

Human papilloma virus (HPV) vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against certain single viral diseases

Hydralazine

Section	Indications
Antihypertensive medicines ◦ Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride) ◦ Oral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride) ◦ Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)	Essential hypertension Gestational hypertension

Hydrochlorothiazide

Section	Indications
Antihypertensive medicines ◦ Oral > Liquid: 50 mg per 5 mL ◦ Oral > Solid: 25 mg; 12.5 mg	Essential hypertension
Diuretics ◦ Oral > Solid > dosage form: 25 mg; 12.5 mg	Oedema
Medicines used in heart failure ◦ Oral > Liquid: 50 mg per 5 mL ◦ Oral > Solid: 25 mg	Heart failure

Hydrocortisone

Section	Indications
Hormones and antihormones ◦ Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)	Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Unspecified malignant neoplasms of unspecified sites
Ophthalmological preparations > Anti-inflammatory agents ◦ Local > Ophthalmological > Ointment: 1% (acetate)	Scleritis Anterior uveitis
Antiallergics and medicines used in anaphylaxis ◦ Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)	Anaphylaxis
Anti-inflammatory medicines ◦ Local > Rectal > Suppository: 25 mg (acetate) ◦ Local > Rectal > Retention enema: 100 mg per 60 mL	Crohn disease site Ulcerative colitis
Dermatological medicines > Anti-inflammatory and antipruritic medicines ◦ Local > Topical > Cream: 1% (acetate) ◦ Local > Topical > Ointment: 1% (acetate)	Dermatitis or eczema Pruritus due to skin disorder Psoriasis of unspecified type Lichen planus
Adrenal hormones and synthetic substitutes ◦ Oral > Solid > tablet: 5 mg; 10 mg; 20 mg ◦ Oral > Solid > granules: 0.5 mg in capsule; 1 mg in capsule; 2 mg in capsule; 5 mg in capsule	Adrenocortical insufficiency

Hydromorphone

Section	Indications
Opioid analgesics	Therapeutic equivalent to morphine pour Pain

Hydroxocobalamin

Section	Indications
Antianaemia medicines ◦ Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)	Megaloblastic anaemia due to vitamin B12 deficiency

Hydroxychloroquine

Section	Indications
Antimalarial medicines > Medicines for chemoprevention	Therapeutic equivalent to chloroquine pour Malaria due to Plasmodium falciparum
Disease-modifying anti-rheumatic drugs (DMARDs) ◦ Oral > Solid: 200 mg (as sulfate)	Systemic lupus erythematosus Cutaneous lupus erythematosus of unspecified type

Hydroxyurea (hydroxycarbamide)

Section	Indications
Cytotoxic medicines ◦ Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g ◦ Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg	Squamous cell carcinoma of oropharynx Chronic myeloid leukaemia, not elsewhere classified
Medicines for haemoglobinopathies ◦ Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg	Other specified sickle cell disorders or other haemoglobinopathies

Hyoscine butylbromide

Section	Indications
Medicines for other common symptoms in palliative care ◦ Parenteral > General injections > unspecified: 20 mg per mL injection	Palliative care

Hyoscine hydrobromide

Section	Indications
Medicines for other common symptoms in palliative care ◦ Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch ◦ Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection	Palliative care

Hypochlorous acid

Section	Indications
Disinfectants ◦ Solution (aqueous): containing hypochlorous acid ≥ 150 parts per million	Disinfectant, not elsewhere classified
Antiseptics ◦ Solution (aqueous): containing hypochlorous acid ≥ 150 parts per million	Hypochlorite

Hypromellose

Section	Indications
Ophthalmological preparations ◦ Local > Ophthalmological > Solution (eye drops): 0.3%	Keratoconjunctivitis sicca

Ibrutinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 140 mg	Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Ibuprofen

Section	Indications
Medicines for acute migraine attacks ◦ Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL ◦ Oral > Solid > tablet: 200 mg; 400 mg	Migraine
Medicines administered to the neonate [c] ◦ Parenteral > General injections > IV: 5 mg per mL	Patent arterial duct
Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) ◦ Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL ◦ Oral > Solid > tablet: 200 mg; 400 mg; 600 mg	Pain

Idoxuridine

Section	Indications
Ophthalmological preparations > Anti-infective agents ◦ Local > Ophthalmological > Solution (eye drops): 0.1% ◦ Local > Ophthalmological > Ointment: 0.2%	Herpes simplex keratitis

Ifosfamide

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection ◦ Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection	Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Rhabdomyosarcoma primary site Osteosarcoma of bone or articular cartilage of unspecified sites Germ cell tumour of testis Other specified malignant neoplasms of the ovary Unspecified malignant neoplasms of unspecified sites Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis

Imatinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 100 mg; 400 mg	B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1 Chronic myeloid leukaemia, not elsewhere classified Gastrointestinal stromal tumour of unspecified gastrointestinal sites

Imipenem + cilastatin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection	**Second choix** Therapeutic equivalent to meropenem pour Peritoneal abscess (severe) Therapeutic equivalent to meropenem pour Neutropaenia (high-risk) Therapeutic equivalent to meropenem pour Peritonitis (severe) **Autres indications** Pseudomonas aeruginosa resistant to other antibiotic Antibiotic resistant Acinetobacter baumannii
Antituberculosis medicines	Therapeutic equivalent to meropenem pour Multi-drug resistant Mycobacterium tuberculosis

Imipenem + cilastatin + relebactam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection ◦ Parenteral > General injections > IV: 500 mg (as monohydrate) + 500 mg (as sodium) + 250 mg (as monohydrate) powder for injection	Other specified other antibiotic resistant Enterobacterales Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales

Indapamide

Section	Indications
Antihypertensive medicines	Therapeutic equivalent to hydrochlorothiazide pour Essential hypertension
Medicines used in heart failure	Therapeutic equivalent to hydrochlorothiazide pour Heart failure

Indinavir

Section	Indications
Antiretrovirals > Protease inhibitors ◦ Oral > Solid: 400 mg (as sulfate)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Indometacin

Section	Indications
Medicines administered to the neonate [c]	Therapeutic equivalent to ibuprofen pour Patent arterial duct

Infliximab

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
Medicines for juvenile joint diseases	Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
Dermatological medicines > Medicines affecting skin differentiation and proliferation	Therapeutic equivalent to adalimumab pour Psoriasis of unspecified type

Influenza vaccine (seasonal)

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against influenza

Insulin (analogue, long-acting)

Section	Indications
Insulins ◦ Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution; 100 IU per mL in 10 mL vial solution	Type 2 diabetes mellitus Type 1 diabetes mellitus

Insulin (analogue, rapid-acting)

Section	Indications
Insulins ◦ Parenteral > General injections > SC: 100 IU per 1 mL in 10 mL vial; 100 IU per 1 mL in 3 mL cartridge; 100 IU per 1 mL in 3 mL pre-filled pen	Type 1 diabetes mellitus Type 2 diabetes mellitus

Insulin (human, intermediate-acting)

Section	Indications
Insulins ◦ Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin	Type 2 diabetes mellitus Type 1 diabetes mellitus

Insulin (human, short-acting)

Section	Indications
Insulins ◦ Parenteral > General injections > SC: 40 IU per mL in 10 mL vial solution; 100 IU per mL in 10 mL vial solution; 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution	Type 2 diabetes mellitus Type 1 diabetes mellitus

Insulin analogues

Section	Indications
Insulins ◦ Not specified	Type 2 diabetes mellitus Type 1 diabetes mellitus

Insulin aspart

Section	Indications
Insulins ◦ Parenteral > General injections > SC: 100 IU per mL in 110 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen ◦ Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen	Therapeutic equivalent to insulin (analogue, rapid-acting) pour Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) pour Type 2 diabetes mellitus

Insulin degludec

Section	Indications
Insulins ◦ Parenteral > General injections > SC: 100 units per mL	Therapeutic equivalent to insulin glargine pour Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) pour Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) pour Type 1 diabetes mellitus

Insulin detemir

Section	Indications
Insulins	Therapeutic equivalent to insulin glargine pour Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) pour Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) pour Type 1 diabetes mellitus

Insulin glargine

Section	Indications
Insulins ◦ Parenteral > General injections > SC: 100 units per mL	Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) pour Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) pour Type 1 diabetes mellitus

Insulin glulisine

Section	Indications
Insulins ◦ Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen	Therapeutic equivalent to insulin (analogue, rapid-acting) pour Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) pour Type 2 diabetes mellitus

Insulin lispro

Section	Indications
Insulins ◦ Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen	Therapeutic equivalent to insulin (analogue, rapid-acting) pour Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) pour Type 2 diabetes mellitus

Intraperitoneal dialysis solution

Section	Indications
Peritoneal dialysis solution ◦ Solution: of appropriate composition in accordance with local clinical guidelines.	Care involving peritoneal dialysis

Iodine

Section	Indications
Antiseptics	Therapeutic equivalent to povidone iodine pour Povidone iodine
Vitamins and minerals ◦ Parenteral > General injections > IM: 480 mg per mL in 10 mL ampoule or vial iodized oil (oral or injectable)	Iodine deficiency

Iodine + potassium iodide (Lugol's solution)

Section	Indications
Thyroid hormones and antithyroid medicines ◦ Oral > Liquid: 5% w/v + 10% w/v (aqueous)	Thyrotoxicosis

Iohexol

Section	Indications
Diagnostic agents > Radiocontrast media ◦ Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule	X-ray contrast media, iodinated

Ipecacuanha

Section	Indications
Antidotes and other substances used in poisonings > Non-specific ◦ Oral > Liquid: 0.14% ipecacuanha alkaloids calculated as emetine	Unspecified injury, poisoning or certain other consequences of external causes

Ipilimumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion	Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of oesophagus Melanoma of skin Other specified malignant neoplasms of bronchus or lung

Ipratropium bromide

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease ◦ Respiratory > Inhalation > solution: 20 µg per actuation in pressurized metered dose inhaler	Chronic obstructive pulmonary disease Asthma

Irinotecan

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial	Rhabdomyosarcoma primary site Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis

Isoflurane

Section	Indications
General anaesthetics and oxygen > Inhalational medicines ◦ Respiratory > Inhalation > liquid:	Anaesthetics and therapeutic gases

Isoniazid

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 100 mg per mL ◦ Oral > Solid > dispersible tablet: 100 mg (scored) ◦ Oral > Solid > tablet: 100 mg; 300 mg	Other specified tuberculosis Tuberculosis

Isoniazid + pyrazinamide + rifampicin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg	Tuberculosis

Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim

Section	Indications
Medicines for prevention of HIV-related opportunistic infections ◦ Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)	Other specified prophylactic measures

Isoniazid + rifampicin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 50 mg + 75 mg ◦ Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg	Tuberculosis

Isoniazid + rifapentine

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 300 mg + 300 mg tablet (scored)	Latent tuberculosis

Isoprenaline

Section	Indications
Antiarrhythmic medicines ◦ Parenteral > General injections > IV: 20 µg per mL in ampoule (hydrochloride) ◦ Oral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)	Bradycardia Cardiogenic shock

Isosorbide dinitrate

Section	Indications
Antianginal medicines ◦ Oral > Solid: 5 mg sublingual tablet	Angina pectoris

Itraconazole

Section	Indications
Antifungal medicines ◦ Oral > Liquid: 10 mg per mL ◦ Oral > Solid: 100 mg	Chronic pulmonary aspergillosis Paracoccidioidomycosis Sporotrichosis Histoplasmosis Talaromycosis Chromoblastomycosis

Ivacaftor

Section	Indications
Medicines for cystic fibrosis ◦ Oral > Solid > tablet: 75 mg; 150 mg ◦ Oral > Solid > granules: 59.5 mg; 75 mg	Cystic fibrosis

Ivermectin

Section	Indications
Intestinal anthelminthics ◦ Oral > Solid > tablet: 3 mg	Hookworm diseases Strongyloidiasis Trichuriasis Ancylostomiasis Ascariasis
Antifilarials ◦ Oral > Solid > tablet: 3 mg	Lymphatic filariasis Onchocerciasis
Medicines for ectoparasitic infections ◦ Oral > Solid > tablet: 3 mg	Scabies

Kanamycin

Section	Indications
Ophthalmological preparations > Anti-infective agents	Therapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis

Kanamycin (injection)

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 1000 mg powder for injection (vial)	Multi-drug resistant Mycobacterium tuberculosis

Ketamine

Section	Indications
General anaesthetics and oxygen > Injectable medicines ◦ Parenteral > General injections > unspecified: 10 mg per mL in vial (as hydrochloride); 50 mg per mL in vial (as hydrochloride)	Anaesthetics and therapeutic gases

Ketoconazole

Section	Indications
Medicines for endocrine disorders ◦ Oral > Solid > tablet: 200 mg	Cushing syndrome

Lactulose

Section	Indications
Medicines for other common symptoms in palliative care ◦ Oral > Liquid: 3.3 to 3.4 g per 5 mL oral liquid	Palliative care

Lamivudine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Liquid: 50 mg per 5 mL ◦ Oral > Solid: 150 mg tablet	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Lamivudine + nevirapine + zidovudine

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals	Therapeutic equivalent to emtricitabine + tenofovir pour Contact with or exposure to human immunodeficiency virus Therapeutic equivalent to emtricitabine + tenofovir pour Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Lamivudine + zidovudine

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Lamotrigine

Section	Indications
Antiseizure medicines ◦ Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)	Epilepsy or seizures

Latanoprost

Section	Indications
Ophthalmological preparations > Miotics and antiglaucoma medicines ◦ Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops	Primary open-angle glaucoma

Ledipasvir + sofosbuvir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations ◦ Oral > Solid: 90 mg + 400 mg tablet	Chronic hepatitis C

Lenalidomide

Section	Indications
Immunomodulators ◦ Oral > Solid: 25 mg	Plasma cell myeloma

Lenvatinib

Section	Indications
Targeted therapies ◦ Oral > Solid > capsule: 4 mg; 10 mg	Renal cell carcinoma of kidney, except renal pelvis

Letrozole

Section	Indications
Ovulation inducers ◦ Oral > Solid > dosage form: 2.5 mg	Female infertility without specification whether primary or secondary

Leuprorelin

Section	Indications
Hormones and antihormones ◦ Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe	Malignant neoplasms of breast Malignant neoplasms of prostate

Levamisole

Section	Indications
Intestinal anthelminthics ◦ Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)	Ascariasis

Levetiracetam

Section	Indications
Antiseizure medicines ◦ Oral > Liquid: 100 mg per mL ◦ Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg ◦ Parenteral > General injections > IV: 100 mg per mL in 5 mL ampoule or vial; 5 mg per mL in 100 mL bag; 10 mg per mL in 100 mL bag; 15 mg per mL in 100 mL bag	Epilepsy or seizures Status epilepticus

Levodopa

Section	Indications
Medicines for parkinsonism ◦ Oral > Solid: 250 mg	Parkinson disease

Levodopa + benserazide

Section	Indications
Medicines for parkinsonism	Therapeutic equivalent to levodopa + carbidopa pour Parkinson disease

Levodopa + carbidopa

Section	Indications
Medicines for parkinsonism ◦ Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet	Parkinson disease

Levofloxacin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 100 mg ◦ Oral > Solid > tablet: 250 mg; 500 mg; 750 mg	Multi-drug resistant Mycobacterium tuberculosis

Levonorgestrel

Section	Indications
Oral hormonal contraceptives ◦ Oral > Solid: 750 µg [2]; 1.5 mg [1] ◦ Oral > Solid: 30 µg	Contact with health services for postcoital contraception Contact with health services for contraceptive management
Intrauterine devices ◦ Intrauterine system with reservoir containing 52 mg of levonorgestrel.	Contact with health services for insertion of contraceptive device

Levonorgestrel-releasing implant

Section	Indications
Implantable contraceptives ◦ Implant > Subdermal: 75 mg per rod (two-rods)	Contact with health services for insertion of contraceptive device

Levothyroxine

Section	Indications
Thyroid hormones and antithyroid medicines ◦ Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)	Hypothyroidism

Lidocaine

Section	Indications
Antiarrhythmic medicines ◦ Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)	Ventricular tachyarrhythmia
Local anaesthetics ◦ Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution ◦ Parenteral > Locoregional injections > Other: 1% (hydrochloride); 2% (hydrochloride); 0.5% (hydrochloride) ◦ Local > Topical > unspecified: 2 to 4% (hydrochloride)	Local anaesthetics

Lidocaine + epinephrine

Section	Indications
Local anaesthetics ◦ Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine ◦ Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine	Local anaesthetics

Lindane

Section	Indications
Dermatological medicines > Scabicides and pediculicides ◦ Local > Topical > Cream: 1% ◦ Local > Topical > Lotion: 1%	Scabies

Linezolid

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 2 mg per mL in 300 mL bag ◦ Oral > Liquid: 100 mg per 5 mL powder for oral liquid ◦ Oral > Solid: 400 mg tablet; 600 mg tablet ◦ Oral > Solid > dispersible tablet: 150 mg ◦ Oral > Solid > tablet: 600 mg	Other specified bacterial diseases Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 150 mg (scored) ◦ Oral > Solid > tablet: 600 mg	Multi-drug resistant Mycobacterium tuberculosis

Liraglutide

Section	Indications
Medicines for endocrine disorders ◦ Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen	Obesity
Hypoglycaemic agents	Therapeutic equivalent to semaglutide pour Obesity Therapeutic equivalent to semaglutide pour Type 2 diabetes mellitus

Lisinopril + amlodipine

Section	Indications
Antihypertensive medicines ◦ Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg	Essential hypertension

Lisinopril + hydrochlorothiazide

Section	Indications
Antihypertensive medicines ◦ Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg	Essential hypertension

Lisocabtagene maraleucel

Section	Indications
Antineoplastics and supportive medicines	Therapeutic equivalent to axicabtagene ciloleucel pour Diffuse large B-cell lymphomas

Lithium carbonate

Section	Indications
Medicines for bipolar disorders ◦ Oral > Solid: 300 mg	Bipolar or related disorders

Loperamide

Section	Indications
Medicines for other common symptoms in palliative care ◦ Oral > Solid > dosage form: 2 mg	Palliative care

Lopinavir + ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors ◦ Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable) ◦ Oral > Solid > dosage form: 40 mg + 10 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Loratadine

Section	Indications
Antiallergics and medicines used in anaphylaxis ◦ Oral > Liquid: 1 mg per mL ◦ Oral > Solid > tablet: 10 mg; 5 mg (chewable); 10 mg (chewable)	Allergic or hypersensitivity conditions of unspecified type

Lorazepam

Section	Indications
Antiseizure medicines ◦ Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule	Status epilepticus
Medicines for anxiety disorders	Therapeutic equivalent to diazepam pour Anxiety

Losartan

Section	Indications
Antihypertensive medicines ◦ Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet	Essential hypertension
Medicines used in heart failure ◦ Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet	Heart failure

Lovastatin

Section	Indications
Lipid-lowering agents	Therapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis

Magnesium sulfate

Section	Indications
Antiseizure medicines ◦ Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume) ◦ Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)	Severe pre-eclampsia Eclampsia

Malaria vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against certain specified single infectious diseases

Mannitol

Section	Indications
Diuretics ◦ Parenteral > General injections > IV: 10% solution; 20% solution	Ocular hypertension Cerebral oedema

Measles vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against measles alone

Mebendazole

Section	Indications
Intestinal anthelminthics ◦ Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)	Hookworm diseases Trichuriasis Ascariasis Enterobiasis
Cysticidal medicines ◦ Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)	Other specified echinococcosis

Medroxyprogesterone acetate

Section	Indications
Injectable hormonal contraceptives ◦ Parenteral > General injections > IM: 150 mg per mL in 1 mL vial ◦ Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system	Contact with health services for reasons associated with reproduction
Progestogens ◦ Oral > Solid: 5 mg	Excessive menstruation with irregular cycle

Mefloquine

Section	Indications
Antimalarial medicines > Medicines for curative treatment ◦ Oral > Solid: 250 mg tablet (hydrochloride)	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
Antimalarial medicines > Medicines for chemoprophylaxis in travellers ◦ Oral > Solid > tablet: 250 mg (scored) (as hydrochloride)	Malaria due to Plasmodium falciparum
Antimalarial medicines > Medicines for chemoprevention ◦ Oral > Solid: 250 mg tablet (hydrochloride)	Malaria due to Plasmodium falciparum

Meglumine antimoniate

Section	Indications
Antileishmaniasis medicines ◦ Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule	Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis

Meglumine iotroxate

Section	Indications
Diagnostic agents > Radiocontrast media ◦ Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL	X-ray contrast media, iodinated

Melarsoprol

Section	Indications
Medicines for the treatment of 2nd stage African trypanosomiasis ◦ Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)	Gambiense trypanosomiasis Rhodesiense trypanosomiasis

Melphalan

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 50 mg in vial powder for injection ◦ Oral > Solid: 2 mg	Plasma cell myeloma

Meningococcal meningitis vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against single bacterial diseases

Mercaptopurine

Section	Indications
Cytotoxic medicines ◦ Oral > Liquid: 20 mg per mL ◦ Oral > Solid: 50 mg tablet	Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Langerhans cell histiocytosis Unspecified malignant neoplasms of unspecified sites

Meropenem

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	**Second choix** Neonatal meningitis Peritoneal abscess (severe) Neutropaenia (high-risk) Peritonitis (severe)
Medicines for bacterial central nervous system infections ◦ Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	**Second choix** Neonatal meningitis
Antituberculosis medicines ◦ Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	Multi-drug resistant Mycobacterium tuberculosis

Meropenem + vaborbactam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection	Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Acinetobacter baumannii Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Mesalazine

Section	Indications
Anti-inflammatory medicines	Therapeutic equivalent to sulfasalazine pour Crohn disease site Therapeutic equivalent to sulfasalazine pour Ulcerative colitis

Mesna

Section	Indications
Supportive medicines ◦ Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule ◦ Oral > Solid > tablet: 400 mg; 600 mg ◦ Oral > Other: 600 mg ◦ Oral > Solid > tablet: 400 mg ◦ Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule ◦ Oral > Solid: 400 mg; 600 mg	Rhabdomyosarcoma primary site Germ cell tumour of testis Other specified malignant neoplasms of the ovary Osteosarcoma of bone or articular cartilage of unspecified sites Unspecified malignant neoplasms of unspecified sites Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis Burkitt lymphoma including Burkitt leukaemia

Metformin

Section	Indications
Hypoglycaemic agents ◦ Oral > Solid: 500 mg (hydrochloride)	Type 2 diabetes mellitus

Methadone

Section	Indications
Medicines for opioid use disorders ◦ Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)	Opioid dependence
Opioid analgesics ◦ Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 25 mg per 5 mL (methadone hydrochloride); 50 mg per 5 mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride) ◦ Oral > Solid > tablet: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)	Chronic cancer pain

Methimazole

Section	Indications
Thyroid hormones and antithyroid medicines ◦ Oral > Solid > tablet: 5 mg; 10 mg	Thyrotoxicosis

Methionine

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ Oral > Solid: 250 mg (DL)	Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs

Methotrexate

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection ◦ Oral > Solid: 2.5 mg (as sodium salt) ◦ Parenteral > General injections > IV: 50 mg in vial (as sodium salt)	Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis Osteosarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of breast Unspecified malignant neoplasms of unspecified sites Malignant trophoblastic neoplasms of placenta
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)	Psoriasis of unspecified type
Disease-modifying anti-rheumatic drugs (DMARDs) ◦ Oral > Solid > tablet: 2.5 mg (as sodium salt)	Rheumatoid arthritis, serology unspecified
Immunomodulators for non-malignant disease ◦ Parenteral > General injections > SC: pre-filled syringe in multiple strengths	Crohn disease site Psoriatic arthritis
Medicines for juvenile joint diseases ◦ Oral > Solid > tablet: 2.5 mg (as sodium salt)	Juvenile idiopathic arthritis

Methoxy polyethylene glycol-epoetin beta

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease

Methyldopa

Section	Indications
Antihypertensive medicines ◦ Oral > Solid: 250 mg	Essential hypertension Gestational hypertension

Methylergometrine

Section	Indications
Uterotonics	Therapeutic equivalent to ergometrine pour Postpartum haemorrhage

Methylphenidate

Section	Indications
Medicines for mental and behavioural disorders ◦ Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 20 mg (hydrochloride); 18 mg extended-release (hydrochloride); 27 mg extended-release (hydrochloride); 36 mg extended-release (hydrochloride); 54 mg extended-release (hydrochloride); 72 mg extended-release (hydrochloride) ◦ Oral > Solid > capsule: 10 to 60 mg extended-release (hydrochloride)	Attention deficit hyperactivity disorder

Methylprednisolone

Section	Indications
Hormones and antihormones ◦ Parenteral > General injections > IV: 40 mg in vial (as sodium succinate); 125 mg in vial (as sodium succinate) ◦ Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection; 125 mg in vial (as sodium succinate) powder for injection	Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified

Methylthioninium chloride

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule	Acquired methaemoglobinaemia

Meticillin

Section	Indications
Access group antibiotics	**Premier choix** Therapeutic equivalent to cloxacillin pour Bacterial infection of joint Therapeutic equivalent to cloxacillin pour Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin pour Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Therapeutic equivalent to cloxacillin pour Sepsis without septic shock

Metoclopramide

Section	Indications
Medicines for other common symptoms in palliative care ◦ Oral > Liquid: 5 mg per 5 mL ◦ Oral > Solid: 10 mg (hydrochloride) ◦ Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)	Palliative care
Antiemetic medicines ◦ Oral > Liquid: 5 mg per 5 mL ◦ Oral > Solid: 10 mg (scored) (hydrochloride) ◦ Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)	Nausea or vomiting

Metoprolol

Section	Indications
Antianginal medicines	Therapeutic equivalent to bisoprolol pour Angina pectoris
Antihypertensive medicines	Therapeutic equivalent to bisoprolol pour Essential hypertension
Antiarrhythmic medicines	Therapeutic equivalent to bisoprolol pour Cardiac arrhythmia
Medicines used in heart failure	Therapeutic equivalent to bisoprolol pour Heart failure

Metronidazole

Section	Indications
Antiamoebic and antigiardiasis medicines ◦ Oral > Liquid: 200 mg per 5 mL (as benzoate) ◦ Parenteral > General injections > unspecified: 500 mg in 100 mL vial ◦ Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg	Amoebiasis

Access group antibiotics

- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Local > Rectal > Suppository: 500 mg; 1 g
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
- Oral > Solid > tablet: 500 mg; 200 mg; 250 mg; 400 mg
- Oral > Solid: 200 to 500 mg tablet
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection

Premier choix

Trichomoniasis

Intestinal infections due to Clostridioides difficile

Necrotising fasciitis

co-prescrite avec cefazolin

Other specified prophylactic measures

co-prescrite avec cefotaxime

Peritoneal abscess (mild-moderate)

co-prescrite avec cefotaxime

Peritoneal abscess (severe)

co-prescrite avec cefotaxime

Peritonitis (mild-moderate)

co-prescrite avec cefotaxime

Peritonitis (severe)

co-prescrite avec ceftriaxone

Peritoneal abscess (mild-moderate)

co-prescrite avec ceftriaxone

Peritoneal abscess (severe)

co-prescrite avec ceftriaxone

Peritonitis (mild-moderate)

co-prescrite avec ceftriaxone

Peritonitis (severe)

Second choix

co-prescrite avec ciprofloxacin

Peritoneal abscess (mild-moderate)

co-prescrite avec ciprofloxacin

Peritonitis (mild-moderate)

Bacterial infection of unspecified site

Micafungin

Section	Indications
Antifungal medicines ◦ Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection	Systemic or invasive candidosis

Miconazole

Section	Indications
Dermatological medicines > Antifungal medicines ◦ Local > Topical > Cream: 2% (nitrate) ◦ Local > Topical > Ointment: 2% (nitrate)	Fungal infection of the skin

Midazolam

Section	Indications
Antiseizure medicines ◦ Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration) ◦ Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)	Therapeutic equivalent to lorazepam pour Status epilepticus Status epilepticus

Section	Indications
Medicines for other common symptoms in palliative care ◦ Oral > Liquid: 2 mg per mL ◦ Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial; 5 mg per mL in 1 mL vial; 5 mg per mL in 3 mL vial ◦ Local > Buccal > Solution: ; 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration) ◦ Oral > Solid > dosage form: 7.5 mg; 15 mg	Palliative care
Preoperative medication and sedation for short-term procedures ◦ Parenteral > General injections > IV: 1 mg per mL in 5 vial; 5 mg per mL in 1 mL vial; 5 mg per mL in 3 mL vial ◦ Oral > Liquid: 2 mg per mL ◦ Oral > Solid > dosage form: 15 mg; 7.5 mg	Sedative-hypnotic and anxiolytic drugs

Mifepristone - misoprostol

Section	Indications
Medicines for medical abortion ◦ Oral > Solid > tablet: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package	Unspecified time of fetal death, cause not specified Induced abortion

Miltefosine

Section	Indications
Antileishmaniasis medicines ◦ Oral > Solid: 10 mg; 50 mg	Visceral leishmaniasis Cutaneous leishmaniasis Mucocutaneous leishmaniasis

Misoprostol

Section	Indications
Uterotonics ◦ Local > Vaginal > tablet: 25 µg ◦ Oral > Solid: 200 µg	Unspecified obstetric condition Postpartum haemorrhage
Medicines for medical abortion ◦ Oral > Solid > tablet: 200 µg	Spontaneous abortion, incomplete, without complication

Mometasone

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to budesonide pour Asthma

Mometasone + formoterol

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to budesonide + formoterol pour Asthma

Morphine

Section	Indications
Opioid analgesics ◦ Oral > Liquid: 5 mg per 5 mL (morphine hydrochloride or morphine sulfate); 10 mg per 5 mL (morphine hydrochloride or morphine sulfate) ◦ Parenteral > General injections > unspecified: 1 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 2 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 10 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate) ◦ Oral > Solid > tablet: 10 mg immediate release (morphine sulfate) ◦ Oral > Solid > dosage form: 30 mg slow-release (morphine hydrochloride or morphine sulfate); 200 mg slow-release (morphine hydrochloride or morphine sulfate); 100 mg slow-release (morphine hydrochloride or morphine sulfate); 60 mg slow-release (morphine hydrochloride or morphine sulfate); 10 mg slow-release (morphine hydrochloride or morphine sulfate); 5 mg slow-release (morphine hydrochloride or morphine sulfate) ◦ Oral > Solid > granules: 20 mg (morphine sulfate); 30 mg (morphine sulfate); 60 mg (morphine sulfate); 100 mg (morphine sulfate); 200 mg (morphine sulfate)	Pain
Preoperative medication and sedation for short-term procedures ◦ Parenteral > General injections > IV: 1 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 2 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 10 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate)	Opioids or related analgesics and agents affecting opioid receptors

Moxidectin

Section	Indications
Antifilarials ◦ Oral > Solid > tablet: 2 mg	Therapeutic equivalent to ivermectin pour Lymphatic filariasis Therapeutic equivalent to ivermectin pour Onchocerciasis

Moxifloxacin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 100 mg ◦ Oral > Solid > tablet: 400 mg	Multi-drug resistant Mycobacterium tuberculosis Tuberculosis

Mpox vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against certain single viral diseases

Multiple micronutrient powder

Section	Indications
Vitamins and minerals ◦ Sachets containing: ◦ - iron (elemental) 12.5 mg (as coated ferrous fumarate) ◦ - zinc (elemental) 5 mg ◦ - vitamin A 300 micrograms ◦ - with or without other micronutrients at recommended daily values	Iron deficiency anaemia

Multiple micronutrient supplement

Section	Indications
Other medicines administered to the mother ◦ Tablet containing: ◦ Vit A: 800 mcg retinol activity equivalent ◦ Vit C: 70 mg ◦ Vit D: 5 mcg (200 IU) ◦ Vit E: 10 mg alpha tocopherol equivalent ◦ Vit B1: 1.4 mg ◦ Vit B2: 1.4 mg ◦ Vit B3: 18 mg niacin equivalent ◦ Vit B6: 1.9 mg ◦ Folic acid: 400 mcg ◦ Vit B12: 2.6 mcg ◦ Iron: 30 mg ◦ Iodine: 150 mcg ◦ Zinc: 15 mg ◦ Selenium: 65 mcg ◦ Copper: 2 mg	Maternal care for other specified conditions predominantly related to pregnancy

Mumps vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against mumps alone

Mupirocin

Section	Indications
Dermatological medicines > Anti-infective medicines ◦ Local > Topical > Cream: 2% (as mupirocin calcium) ◦ Local > Topical > Ointment: 2%	Superficial bacterial folliculitis Impetigo

Nadroparin

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to enoxaparin pour Acute ischaemic heart disease Therapeutic equivalent to enoxaparin pour Venous thromboembolism

Nafcillin

Section	Indications
Access group antibiotics	**Premier choix** Therapeutic equivalent to cloxacillin pour Bacterial infection of joint Therapeutic equivalent to cloxacillin pour Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin pour Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Therapeutic equivalent to cloxacillin pour Sepsis without septic shock

Nalidixic acid

Section	Indications
Anti-infective medicines ◦ Oral > Solid: 250 mg; 500 mg	Shigella resistant to unspecified antibiotic

Naloxone

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)	Unintentional exposure to or harmful effects of opioids or related analgesics

Naltrexone

Section	Indications
Medicines for alcohol use disorders ◦ Parenteral > General injections > IM: 380 mg in vial (extended-release) ◦ Oral > Solid > tablet: 50 mg	Disorders due to use of alcohol

Naproxen

Section	Indications
Medicines for acute migraine attacks	Therapeutic equivalent to ibuprofen pour Migraine

Natamycin

Section	Indications
Ophthalmological preparations > Anti-infective agents ◦ Local > Ophthalmological > Suspension: 5% eye drops	Infectious keratitis

Nelfinavir

Section	Indications
Antiretrovirals > Protease inhibitors ◦ Oral > Solid: 250 mg (as mesilate) ◦ Oral > Other: 50 mg per g oral powder	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Neostigmine

Section	Indications
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors ◦ Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate) ◦ Oral > Solid > tablet: 15 mg (neostigmine bromide)	Anticholinesterase reversible Myasthenia gravis
Medicines for myasthenia gravis ◦ Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate) ◦ Oral > Solid > tablet: 15 mg (neostigmine bromide)	Myasthenia gravis

Netilmicin

Section	Indications
Ophthalmological preparations > Anti-infective agents	Therapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis

Nevirapine

Section	Indications
Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors ◦ Oral > Liquid: 50 mg per 5 mL ◦ Oral > Solid > dispersible tablet: 50 mg ◦ Oral > Solid > tablet: 200 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Niclosamide

Section	Indications
Intestinal anthelminthics ◦ Oral > Solid: 500 mg tablet (chewable)	Hymenolepiasis Diphyllobothriasis Taeniasis due to Taenia saginata Taeniasis due to Taenia solium

Nicotinamide

Section	Indications
Vitamins and minerals ◦ Oral > Solid: 50 mg	Pellagra

Nicotine replacement therapy

Section	Indications
Medicines for nicotine use disorders ◦ Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour ◦ Oral > Solid > lozenge: 2 mg; 4 mg lozenge ◦ Local > Buccal > Oral spray: 1 mg per actuation ◦ Local > Buccal > Chewing gum: 2 mg; 4 mg	Nicotine dependence

Nifedipine

Section	Indications
Antioxytocics (tocolytics) ◦ Oral > Solid: 10 mg (immediate-release)	Preterm labour without delivery
Antianginal medicines ◦ Oral > Solid: 10 mg	Angina pectoris
Antihypertensive medicines ◦ Oral > Solid: 10 mg tablet; sustained-release formulations	Essential hypertension

Nifurtimox

Section	Indications
American trypanosomiasis ◦ Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)	Chagas disease
Medicines for the treatment of 2nd stage African trypanosomiasis ◦ Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)	Gambiense trypanosomiasis

Nilotinib

Section	Indications
Targeted therapies ◦ Oral > Solid > capsule: 150 mg; 200 mg	Chronic myelogenous leukaemia, BCR-ABL1-positive

Nilutamide

Section	Indications
Hormones and antihormones	Therapeutic equivalent to bicalutamide pour Malignant neoplasms of prostate

Nitrofurantoin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 25 mg per 5 mL oral liquid ◦ Oral > Solid > dosage form: 100 mg; 50 mg	**Premier choix** Infectious cystitis

Nitrous oxide

Section	Indications
General anaesthetics and oxygen > Inhalational medicines ◦ Respiratory > Inhalation:	Anaesthetics and therapeutic gases

Nivolumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion ◦ Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion ◦ Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion	Therapeutic equivalent to pembrolizumab pour Melanoma of skin Melanoma of skin Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of oesophagus Adenocarcinoma of oesophagogastric junction Adenocarcinoma of stomach Other specified malignant neoplasms of bronchus or lung

Norethisterone

Section	Indications
Oral hormonal contraceptives ◦ Oral > Solid: 350 µg	Contact with health services for contraceptive management
Progestogens ◦ Oral > Solid: 5 mg	Excessive menstruation with irregular cycle Therapeutic equivalent to medroxyprogesterone acetate pour Excessive menstruation with irregular cycle

Norethisterone enantate

Section	Indications
Injectable hormonal contraceptives ◦ Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution	Contact with health services for reasons associated with reproduction

Normal immunoglobulin

Section	Indications
Human immunoglobulins ◦ Parenteral > General injections > IV: 5% protein solution; 10% protein solution ◦ Parenteral > General injections > IM: 16% protein solution ◦ Parenteral > General injections > SC: 15% protein solution; 16% protein solution	Primary immunodeficiencies Mucocutaneous lymph node syndrome Langerhans cell histiocytosis
Medicines for Guillain-Barré syndrome ◦ Parenteral > General injections > IV: 5% protein solution; 10% protein solution	Acute inflammatory demyelinating polyneuropathy

Nystatin

Section	Indications
Antifungal medicines ◦ Oral > Liquid: 100000 IU per mL ◦ Local > Topical > Other: 100000 IU pessary ◦ Oral > Solid > dosage form: 500000 IU ◦ Oral > Solid > lozenge: 100000 IU	Candidosis

Ocrelizumab

Section	Indications
Medicines for multiple sclerosis ◦ Parenteral > General injections > IV: 30 mg per mL in 10 mL vial ◦ Parenteral > General injections > IV: 30 mg per mL in 10 vial concentrate for solution	Relapsing-remitting multiple sclerosis Multiple sclerosis

Octreotide

Section	Indications
Medicines for disorders of the pituitary hormone system ◦ Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent ◦ Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)	Acromegaly or pituitary gigantism

Ofloxacin

Section	Indications
Ear, nose and throat medicines [c]	Therapeutic equivalent to ciprofloxacin pour Infectious diseases of external ear
Ophthalmological preparations > Anti-infective agents ◦ Local > Ophthalmological > Solution (eye drops): 0.3%	Other specified conjunctivitis Infectious keratitis
Antituberculosis medicines ◦ Oral > Solid: 200 mg; 400 mg	Multi-drug resistant Mycobacterium tuberculosis

Olanzapine

Section	Indications
Medicines for psychotic disorders ◦ Parenteral > General injections > IM: 10 mg in vial powder for injection	Therapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders

Omadacycline

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 100 mg lyophilized powder for injection ◦ Oral > Solid: 300 mg	Methicillin resistant Staphylococcus aureus

Ombitasvir + paritaprevir + ritonavir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations ◦ Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet	Chronic hepatitis C

Omeprazole

Section	Indications
Antiulcer medicines ◦ Parenteral > General injections > IV: 40 mg in vial ◦ Oral > Liquid: 1 mg per mL powder for oral liquid; 4 mg per mL powder for oral liquid ◦ Oral > Solid > dosage form: 10 mg; 20 mg; 40 mg	Gastrointestinal bleeding Peptic ulcer, site unspecified Gastro-oesophageal reflux disease

Ondansetron

Section	Indications
Medicines for other common symptoms in palliative care ◦ Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate); 2 mg per mL in 4 mL ampoule (as hydrochloride dihydrate) ◦ Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate) ◦ Oral > Solid: 4 mg (as hydrochloride dihydrate); 8 mg (as hydrochloride dihydrate)	Palliative care
Antiemetic medicines ◦ Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate); 2 mg per mL in 4 mL ampoule ◦ Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate) ◦ Oral > Solid > dosage form: 4 mg (as hydrochloride dihydrate); 8 mg (as hydrochloride dihydrate); 24 mg (as hydrochloride dihydrate)	Nausea or vomiting

Oral rehydration salts

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Oral ◦ Powder for dilution in 200 mL, 500 mL, 1 L: ◦ ◦ - glucose 75 mEq or mmol/L ◦ - sodium 75 mEq or mmol/L ◦ - chloride 65 mEq or mmol/L ◦ - potassium 20 mEq or mmol/L ◦ - citrate 10 mEq or mmol/L ◦ - osmolarity 245 mOsm/L ◦ - glucose 13.5 g/L ◦ - sodium chloride 2.6 g/L ◦ - potassium chloride 1.5 g/L ◦ - trisodium citrate dihydrate 2.9 g/L	Other specified disorders of fluid, electrolyte or acid-base balance
Oral rehydration ◦ Powder for dilution in 200 mL, 500 mL, 1 L: ◦ ◦ - glucose 75 mEq or mmol/L ◦ - sodium 75 mEq or mmol/L ◦ - chloride 65 mEq or mmol/L ◦ - potassium 20 mEq or mmol/L ◦ - citrate 10 mEq or mmol/L ◦ - osmolarity 245 mOsm/L ◦ - glucose 13.5 g/L ◦ - sodium chloride 2.6 g/L ◦ - potassium chloride 1.5 g/L ◦ - trisodium citrate dihydrate 2.9 g/L	Diarrhoea

Oral rehydration salts - zinc sulfate

Section	Indications
Medicines used in diarrhoea ◦ Oral > Other: ORS powder for dilution and zinc sulfate dispersible tablet 20 mg (co-packaged)	Diarrhoea

Oseltamivir

Section	Indications
Other antivirals ◦ Oral > Liquid: 6 mg per mL (as phosphate) powder for oral liquid ◦ Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)	Influenza due to identified seasonal influenza virus

Osimertinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)	Other specified malignant neoplasms of bronchus or lung

Oxacillin

Section	Indications
Access group antibiotics	**Premier choix** Therapeutic equivalent to cloxacillin pour Bacterial infection of joint Therapeutic equivalent to cloxacillin pour Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin pour Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Therapeutic equivalent to cloxacillin pour Sepsis without septic shock

Oxaliplatin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial	Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon

Oxamniquine

Section	Indications
Antischistosomals and other antitrematode medicines ◦ Oral > Liquid: 250 mg per 5 mL ◦ Oral > Solid > capsule: 250 mg	Schistosomiasis due to Schistosoma mansoni

Oxazolindinones

Section	Indications
Reserve group antibiotics ◦ .	Other specified bacterial diseases

Oxycodone

Section	Indications
Opioid analgesics	Therapeutic equivalent to morphine pour Pain

Oxygen

Section	Indications
General anaesthetics and oxygen > Inhalational medicines ◦ Respiratory > Inhalation: (medical gas)	Anaesthetics and therapeutic gases
Medical gases ◦ Respiratory > Inhalation:	Respiratory failure as acute or chronic

Oxytetracycline

Section	Indications
Ophthalmological preparations > Anti-infective agents	Therapeutic equivalent to tetracycline pour Other specified conjunctivitis Therapeutic equivalent to tetracycline pour Infectious keratitis Therapeutic equivalent to tetracycline pour Infectious blepharitis Therapeutic equivalent to tetracycline pour Trachoma

Oxytocin

Section	Indications
Uterotonics ◦ Parenteral > General injections > unspecified: 10 IU per mL	Postpartum haemorrhage

P-aminosalicylate sodium

Section	Indications
Antituberculosis medicines ◦ Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution	Multi-drug resistant Mycobacterium tuberculosis

P-aminosalicylic acid

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 4 g granules in sachet	Multi-drug resistant Mycobacterium tuberculosis

Paclitaxel

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 6 mg per mL	Malignant neoplasms of cervix uteri Kaposi sarcoma of unspecified primary site Other specified malignant neoplasms of the ovary Malignant neoplasms of nasopharynx Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast Malignant neoplasms of breast

Palbociclib

Section	Indications
Targeted therapies ◦ Oral > Solid: 75 mg; 100 mg; 125 mg	Other specified malignant neoplasms of breast

Paliperidone

Section	Indications
Medicines for psychotic disorders ◦ Parenteral > General injections > IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)	Therapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders

Palonosetron

Section	Indications
Medicines for other common symptoms in palliative care	Therapeutic equivalent to ondansetron pour Palliative care
Antiemetic medicines	Therapeutic equivalent to ondansetron pour Nausea or vomiting

Pancreatic enzymes

Section	Indications
Gastrointestinal medicines ◦ Capsule (modified release): 10 000 lipase units + 8000 amylase units + 600 protease units; 25 000 lipase units + 18 000 amylase units + 1000 protease units. ◦ *Units expressed in Ph. Eur	Enzyme intestinal
Medicines for cystic fibrosis ◦ Capsule (modified release): 10 000 lipase units + 8000 amylase units + 600 protease units; 25 000 lipase units + 18 000 amylase units + 1000 protease units. ◦ *Units expressed in Ph. Eur	Cystic fibrosis

Panitumumab

Section	Indications
Targeted therapies ◦ Parenteral > General injections > IV: 20 mg per mL in 5 mL vial concentrate for solution for infusion; 20 mg per mL in 20 mL vial	Other specified malignant neoplasms of large intestine

Paracetamol (acetaminophen)

Section	Indications
Medicines for acute migraine attacks ◦ Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL ◦ Local > Rectal > Suppository: 250 mg ◦ Oral > Solid > dispersible tablet: 100 mg; 250 mg ◦ Oral > Solid > tablet: 250 mg; 325 mg; 500 mg	Migraine
Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) ◦ Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL ◦ Local > Rectal > Suppository: 100 mg; 250 mg ◦ Oral > Solid > dispersible tablet: 100 mg; 250 mg ◦ Oral > Solid > tablet: 250 mg; 325 mg; 500 mg	Pain

Paromomycin

Section	Indications
Antileishmaniasis medicines ◦ Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)	Visceral leishmaniasis
Antiamoebic and antigiardiasis medicines ◦ Oral > Liquid: 125 mg per 5 mL as sulfate ◦ Oral > Solid: 250 mg as sulfate	Amoebiasis

Paroxetine

Section	Indications
Medicines for anxiety disorders	Therapeutic equivalent to fluoxetine pour Generalised anxiety disorder

Pegaspargase

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection	Lymphoid leukaemia, not elsewhere classified

Pegfilgrastim

Section	Indications
Immunomodulators ◦ Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe	Acquired neutropaenia

Pegylated interferon alfa (2a)

Section	Indications
Medicines for hepatitis C > Other antivirals for hepatitis C ◦ Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe	Chronic hepatitis C

Pegylated interferon alfa (2b)

Section	Indications
Medicines for hepatitis C > Other antivirals for hepatitis C ◦ Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe	Chronic hepatitis C

Pembrolizumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 25 mg per mL in 4 mL vial ◦ Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion ◦ Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection	Melanoma of skin Other specified malignant neoplasms of large intestine Malignant neoplasms of cervix uteri Adenocarcinoma of stomach Malignant neoplasms of oesophagogastric junction Squamous cell carcinoma of hypopharynx and variants Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx Squamous cell carcinoma of oropharynx Squamous cell carcinoma of nasopharynx Therapeutic equivalent to nivolumab pour Melanoma of skin Renal cell carcinoma of kidney, except renal pelvis Carcinoma of breast, specialised type Squamous cell carcinoma of oesophagus Other specified malignant neoplasms of bronchus or lung

Penicillamine

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ Oral > Solid: 250 mg	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
Disease-modifying anti-rheumatic drugs (DMARDs) ◦ Oral > Solid: 250 mg	Rheumatoid arthritis, serology unspecified

Pentamidine

Section	Indications
Antileishmaniasis medicines ◦ Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)	Visceral leishmaniasis
Medicines for the treatment of 1st stage African trypanosomiasis ◦ Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection	Gambiense trypanosomiasis
Antipneumocystosis and antitoxoplasmosis medicines ◦ Oral > Solid > tablet: 200 mg (as isethionate); 300 mg (as isethionate)	Pneumocystosis

Perindopril + amlodipine + indapamide

Section	Indications
Antihypertensive medicines ◦ Oral > Solid > dosage form: 5 mg (arginine) + 5 mg + 1.25 mg; 5 mg (arginine) + 10 mg + 1.25 mg; 10 mg (arginine) + 5 mg + 2.5 mg; 10 mg (arginine) + 10 mg + 2.5 mg	Essential hypertension

Permethrin

Section	Indications
Dermatological medicines > Scabicides and pediculicides ◦ Local > Topical > Lotion: 1% ◦ Local > Topical > Cream: 5%	Pediculosis corporis Pediculosis capitis Scabies

Pertussis vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against pertussis alone

Pertuzumab

Section	Indications
Targeted therapies ◦ Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution	Carcinoma of breast, specialised type

Phenelzine

Section	Indications
Medicines for depressive disorders ◦ Oral > Solid > dosage form: 15 mg (as sulfate)	Other specified depressive disorders

Phenobarbital

Section	Indications
Antiseizure medicines ◦ Parenteral > General injections > IV: 200 mg per mL (phenobarbital sodium); 30 mg per mL (phenobarbital sodium); 60 mg per mL (phenobarbital sodium) ◦ Oral > Liquid: 15 mg per 5 mL ◦ Oral > Solid > tablet: 15 mg; 30 mg; 60 mg; 100 mg	Status epilepticus Epilepsy or seizures

Phenoxymethylpenicillin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid ◦ Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt) ◦ Oral > Solid: 250 mg (as potassium salt) tablet	**Premier choix** Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Periapical abscess without sinus Acute pharyngitis **Autres indications** Bacterial infection of unspecified site

Phenytoin

Section	Indications
Antiseizure medicines ◦ Oral > Liquid: 30 mg per 5 mL (phenytoin) ◦ Parenteral > General injections > unspecified: 50 mg per mL in vial (phenytoin sodium) ◦ Oral > Solid > tablet: 50 mg (phenytoin) (chewable) ◦ Oral > Solid > dosage form: 25 mg (phenytoin sodium); 50 mg (phenytoin sodium); 100 mg (phenytoin sodium)	Epilepsy or seizures

Phosphorus

Section	Indications
Medicines for endocrine disorders ◦ Oral > Other: 500 mg in sachet (elemental phosphorus) granules ◦ Oral > Solid > tablet: 250 mg (elemental phosphorus); 500 mg (elemental phosphorus); 500 mg (elemental phosphorus) (effervescent)	Hypophosphataemic rickets

Phytomenadione

Section	Indications
Medicines affecting coagulation ◦ Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule; 2 mg per 0.2 mL in ampoule mixed micelle solution; 10 mg per mL in ampoule mixed micelle solution; 1 mg per 0.5 mL in ampoule ◦ Oral > Solid > tablet: 5 mg tablet	Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors Haemorrhagic or haematological disorders of fetus or newborn

Pilocarpine

Section	Indications
Ophthalmological preparations > Miotics and antiglaucoma medicines ◦ Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)	Acute angle closure with pupillary block Ocular hypertension Primary open-angle glaucoma

Piperacillin + tazobactam

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection	**Premier choix** Other specified pneumonia (Hospital-acquired pneumonia) Neutropaenia (high-risk) Peritoneal abscess (severe) Peritonitis (severe) co-prescrite avec clindamycin Necrotising fasciitis

Platelets

Section	Indications
Blood and blood components ◦ Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

Plazomicin

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 500 mg per 10 mL	Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Escherichia coli Carbapenem resistant Klebsiella pneumoniae

Pneumococcal vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against single bacterial diseases

Podophyllotoxin

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation	Therapeutic equivalent to podophyllum resin pour Plantar warts Therapeutic equivalent to podophyllum resin pour Anogenital warts

Podophyllum resin

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Local > Topical > Solution: 10 to 25%	Plantar warts Anogenital warts

Poliomyelitis vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against poliomyelitis

Polygeline

Section	Indications
Plasma substitutes ◦ Parenteral > General injections > IV: 3.5% injectable solution ◦ Parenteral > General injections > IV: 3.5% in solution	Therapeutic equivalent to dextran 70 pour Hypovolaemia Hypovolaemia

Polymyxin B (injection)

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)	Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Acinetobacter baumannii Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Polymyxins

Section	Indications
Reserve group antibiotics ◦ .	Other specified bacterial diseases

Porcatant alfa

Section	Indications
Medicines administered to the neonate [c] ◦ Respiratory > Suspension: 80 mg per mL for intratracheal instillation	Respiratory distress syndrome of newborn

Potassium chloride

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Parenteral ◦ Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL)	Hypokalaemia
Solutions correcting water, electrolyte and acid-base disturbances > Oral ◦ Oral > Liquid: powder for solution	Hypokalaemia

Potassium ferric hexacyanoferrate (Prussian blue)

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ Oral > Solid: Powder for oral administration	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Potassium iodide

Section	Indications
Thyroid hormones and antithyroid medicines ◦ Oral > Solid > tablet: 65 mg (scored)	Thyrotoxicosis
Antifungal medicines ◦ Local > Topical > Solution: Saturated solution	Sporotrichosis

Potassium permanganate

Section	Indications
Dermatological medicines > Anti-infective medicines ◦ Local > Topical > Solution: aqueous solution: 1:10 000	Tropical phagedaenic ulcer Pemphigus Other specified pyogenic bacterial infection of skin or subcutaneous tissue Impetigo

Povidone iodine

Section	Indications
Antiseptics ◦ Local > Topical > Solution: 10% (equivalent to 1% available iodine)	Povidone iodine

Pralidoxime

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ .	Exposure to or harmful effects of undetermined intent of pesticides

Pramipexole

Section	Indications
Medicines for central nervous system disorders ◦ Oral > Solid: 125 µg immediate-release; 250 mg immediate-release; 500 µg immediate-release; 750 µg immediate-release; 1 mg immediate-release; 1.5 mg immediate-release; 375 µg extended-release; 750 µg extended-release; 1.5 mg extended-release; 2.25 mg extended-release; 3 mg extended-release; 3.75 mg extended-release; 4.5 extended-release	Parkinson disease

Pravastatin

Section	Indications
Lipid-lowering agents	Therapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis

Praziquantel

Section	Indications
Cysticidal medicines ◦ Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg	Cysticercosis of central nervous system
Antischistosomals and other antitrematode medicines ◦ Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg	Paragonimiasis Clonorchiasis Opisthorchiasis Schistosomiasis
Intestinal anthelminthics ◦ Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg	Diphyllobothriasis Taeniasis due to Taenia saginata Hymenolepiasis Taeniasis due to Taenia solium

Precipitated sulfur

Section	Indications
Dermatological medicines > Scabicides and pediculicides ◦ Local > Topical > Ointment:	Therapeutic equivalent to benzyl benzoate pour Pediculosis corporis Therapeutic equivalent to benzyl benzoate pour Pediculosis capitis Therapeutic equivalent to benzyl benzoate pour Pthiriasis Therapeutic equivalent to benzyl benzoate pour Scabies

Prednisolone

Section	Indications
Anti-inflammatory medicines ◦ Local > Rectal > Retention enema: ◦ Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)	Therapeutic equivalent to hydrocortisone pour Crohn disease site Crohn disease site Ulcerative colitis

Hormones and antihormones ◦ Oral > Liquid: 5 mg per mL ◦ Oral > Solid: 5 mg; 25 mg	Lymphoid leukaemia, not elsewhere classified Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma Malignant neoplasms of prostate Follicular lymphoma
Antiallergics and medicines used in anaphylaxis ◦ Oral > Liquid: 5 mg per mL ◦ Oral > Solid: 5 mg; 25 mg	Allergic or hypersensitivity conditions of unspecified type
Ophthalmological preparations > Anti-inflammatory agents ◦ Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)	Scleritis Anterior uveitis
Adrenal hormones and synthetic substitutes ◦ Oral > Solid > tablet: 1 mg	Adrenocortical insufficiency
Medicines for cluster headache ◦ Oral > Solid > tablet: 5 mg; 25 mg	Trigeminal autonomic cephalalgias
Antiseizure medicines ◦ Oral > Liquid: 1 mg per mL ◦ Oral > Solid > tablet: 1 mg; 5 mg; 10 mg	Infantile spasms

Prednisone

Section	Indications
Hormones and antihormones	Therapeutic equivalent to prednisolone pour Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone pour Diffuse large B-cell lymphoma, not otherwise specified Therapeutic equivalent to prednisolone pour Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone pour Plasma cell myeloma Therapeutic equivalent to prednisolone pour Anaplastic large cell lymphoma, ALK-negative Therapeutic equivalent to prednisolone pour Anaplastic large cell lymphoma, ALK-positive Therapeutic equivalent to prednisolone pour Langerhans cell histiocytosis Therapeutic equivalent to prednisolone pour Hodgkin lymphoma Therapeutic equivalent to prednisolone pour Malignant neoplasms of prostate Therapeutic equivalent to prednisolone pour Follicular lymphoma
Antiallergics and medicines used in anaphylaxis	Therapeutic equivalent to prednisolone pour Allergic or hypersensitivity conditions of unspecified type
Adrenal hormones and synthetic substitutes ◦ Oral > Solid > tablet: 1 mg	Therapeutic equivalent to prednisolone pour Adrenocortical insufficiency

Pretomanid

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > tablet: 200 mg	Multi-drug resistant Mycobacterium tuberculosis

Primaquine

Section	Indications
Antimalarial medicines > Medicines for curative treatment ◦ Oral > Solid > tablet: 7.5 mg (as phosphate); 15 mg (as phosphate)	Malaria due to Plasmodium ovale Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Probenecid

Section	Indications
Medicines used to treat gout ◦ Oral > Solid: 500 mg	Gout

Procainamide

Section	Indications
Antiarrhythmic medicines ◦ Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule (hydrochloride) ◦ Oral > Solid: 500 mg (hydrochloride); 250 mg (hydrochloride)	Cardiac arrhythmia

Procaine benzylpenicillin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection	**Premier choix** Congenital syphilis [children] **Second choix** Syphilis

Procarbazine

Section	Indications
Cytotoxic medicines ◦ Oral > Solid: 50 mg (as hydrochloride) ◦ Oral > Solid > capsule: 50 mg (as hydrochloride)	Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma

Progesterone vaginal ring

Section	Indications
Intravaginal contraceptives ◦ Local > Vaginal > vaginal ring: 2.074 g micronized progesterone	Contact with health services for contraceptive management

Proguanil

Section	Indications
Antimalarial medicines > Medicines for chemoprevention ◦ Oral > Solid: 100 mg tablet (hydrochloride)	Malaria due to Plasmodium falciparum

Promethazine

Section	Indications
Antiemetic medicines ◦ Oral > Liquid: 5 mg per 5 mL (hydrochloride) ◦ Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride) ◦ Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule	Nausea or vomiting

Propanol

Section	Indications
Antiseptics	Therapeutic equivalent to ethanol pour Denatured alcohol

Propofol

Section	Indications
General anaesthetics and oxygen > Injectable medicines ◦ Parenteral > General injections > IV: 10 mg per mL; 20 mg per mL	Anaesthetics and therapeutic gases

Propranolol

Section	Indications
Antianginal medicines ◦ Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride) ◦ Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)	Angina pectoris
Antihypertensive medicines ◦ Oral > Solid: 80 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)	Essential hypertension
Medicines for migraine prophylaxis ◦ Oral > Solid > tablet: 40 mg (hydrochloride); 10 mg (hydrochloride)	Migraine
Antiarrhythmic medicines ◦ Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride) ◦ Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)	Cardiac arrhythmia

Propylthiouracil

Section	Indications
Thyroid hormones and antithyroid medicines ◦ Oral > Solid: 50 mg	Thyrotoxicosis

Protamine sulfate

Section	Indications
Medicines affecting coagulation ◦ Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule or vial	Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors

Protionamide

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > tablet: 250 mg (scored)	Therapeutic equivalent to ethionamide pour Multi-drug resistant Mycobacterium tuberculosis

Pyrantel

Section	Indications
Intestinal anthelminthics ◦ Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)	Hookworm diseases Trichuriasis Ascariasis Enterobiasis

Pyrazinamide

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 150 mg ◦ Oral > Solid > tablet: 400 mg; 500 mg	Tuberculosis

Pyridostigmine

Section	Indications
Medicines for myasthenia gravis ◦ Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide) ◦ Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide)	Myasthenia gravis
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors ◦ Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide) ◦ Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide)	Myasthenia gravis

Pyridoxine

Section	Indications
Vitamins and minerals ◦ Oral > Solid > tablet: 25 mg (hydrochloride); 10 mg (hydrochloride)	Other specified polyneuropathy Vitamin B6 deficiency Sideroblastic anaemia

Pyrimethamine

Section	Indications
Antipneumocystosis and antitoxoplasmosis medicines ◦ Oral > Solid: 25 mg	Toxoplasmosis

Quetiapine

Section	Indications
Medicines for psychotic disorders	Therapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders
Medicines for bipolar disorders ◦ Oral > Solid > tablet: 25 mg (immediate-release); 100 mg (immediate-release); 150 mg (immediate-release); 200 mg (immediate-release); 300 mg (immediate-release); 50 mg (modified-release); 150 mg (modified-release); 200 mg (modified-release); 300 mg (modified-release); 400 mg (modified-release)	Bipolar or related disorders

Quinidine

Section	Indications
Antiarrhythmic medicines ◦ Oral > Solid: 200 mg (sulfate)	Cardiac arrhythmia

Quinine

Section	Indications
Antimalarial medicines > Medicines for curative treatment ◦ Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion; 60 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion	Malaria due to Plasmodium falciparum

Rabies vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against rabies

Raltegravir

Section	Indications
Antiretrovirals > Integrase inhibitors ◦ Oral > Liquid: 100 mg granules for oral suspension ◦ Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Ranibizumab

Section	Indications
Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations ◦ .	Retinal venous occlusions Diabetic macular oedema Degenerative high myopia Age-related macular degeneration

Ranitidine

Section	Indications
Antiulcer medicines ◦ Oral > Liquid: 75 mg per 5 mL (as hydrochloride) ◦ Oral > Solid: 150 mg (as hydrochloride) ◦ Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)	Peptic ulcer, site unspecified Gastro-oesophageal reflux disease

Rasburicase

Section	Indications
Supportive medicines ◦ Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution	Tumour lysis syndrome

Ravidasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations ◦ Oral > Solid > tablet: 200 mg	Chronic hepatitis C

Ready to use therapeutic food

Section	Indications
Therapeutic foods ◦ Biscuit or paste of nutritional composition as determined by the UN joint statement on the community-based management of severe acute malnutrition and Codex alimentarius guidelines.	Acute malnutrition in infants, children or adolescents

Realgar-indigo naturalis formulation

Section	Indications
Cytotoxic medicines ◦ Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)	Acute myeloid leukaemia with recurrent genetic abnormalities

Red blood cells

Section	Indications
Blood and blood components ◦ Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

Resin-based composite (high-viscosity)

Section	Indications
Dental medicines and preparations ◦ Local > Topical > Other: Single-use capsule or multi-use syringe	Dental caries

Resin-based composite (low-viscosity)

Section	Indications
Dental medicines and preparations ◦ Local > Topical > Other: Single-use applicator or multi-use bottle	Dental caries

Respiratory syncytial virus vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against certain single viral diseases

Retinol

Section	Indications
Vitamins and minerals ◦ Parenteral > General injections > IM: 50000 IU per mL in 2 mL ampoule or vial water-miscible (as palmitate) ◦ Oral > Liquid: 100000 IU per mL (as palmitate or acetate) ◦ Oral > Solid > capsule: 200000 IU (as palmitate or acetate) soft capsule; 50000 IU (as palmitate); 100000 IU (as palmitate or acetate) soft capsule	Vitamin A deficiency

Ribavirin

Section	Indications
Other antivirals ◦ Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution ◦ Oral > Solid: 200 mg; 400 mg; 600 mg	Viral haemorrhagic fever, not elsewhere classified
Medicines for hepatitis C > Other antivirals for hepatitis C ◦ Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution ◦ Oral > Solid: 200 mg; 400 mg; 600 mg	Chronic hepatitis C

Ribociclib

Section	Indications
Targeted therapies	Therapeutic equivalent to palbociclib pour Other specified malignant neoplasms of breast

Riboflavin

Section	Indications
Vitamins and minerals ◦ Oral > Solid: 5 mg	Vitamin B2 deficiency

Rifabutin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 150 mg	Tuberculosis

Rifampicin

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 600 mg in vial powder for injection ◦ Oral > Liquid: 20 mg per mL ◦ Oral > Solid: 150 mg; 300 mg	Other specified tuberculosis Tuberculosis
Antileprosy medicines ◦ Oral > Liquid: 20 mg per mL ◦ Oral > Solid: 150 mg; 300 mg	Leprosy

Rifapentine

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 150 mg ◦ Oral > Solid > tablet: 150 mg; 300 mg	Latent tuberculosis Tuberculosis

Risdiplam

Section	Indications
Medicines for neurological disorders ◦ Oral > Liquid: 0.75 mg per mL powder for oral liquid ◦ Oral > Solid > dispersible tablet: 5 mg	Spinal muscular atrophy

Risperidone

Section	Indications
Medicines for psychotic disorders ◦ Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg ◦ Parenteral > General injections > IM:	Schizophrenia or other primary psychotic disorders Therapeutic equivalent to paliperidone pour Schizophrenia or other primary psychotic disorders

Ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors ◦ Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Rituximab

Section	Indications
Targeted therapies ◦ Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial	Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Burkitt lymphoma including Burkitt leukaemia Follicular lymphoma
Medicines for multiple sclerosis ◦ Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial	Multiple sclerosis

Rivaroxaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation Therapeutic equivalent to dabigatran pour Venous thromboembolism

Ropinirole

Section	Indications
Medicines for central nervous system disorders ◦ Oral > Solid: 0.25 mg immediate-release; 0.5 mg immediate-release; 1 mg immediate-release; 2 immediate-release; 3 mg immediate-release; 4 mg immediate-release; 5 mg immediate-release; 2 mg extended-release; 4 mg extended-release; 6 mg extended-release; 8 mg extended-release; 12 mg extended-release	Parkinson disease

Rotavirus vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against certain single viral diseases

Rubella vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against rubella alone

Salbutamol

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease ◦ Parenteral > General injections > IV: 500 µg per mL in 1 mL ampoule (as sulfate); 500 µg per mL in 5 mL ampoule (as sulfate) ◦ Respiratory > Inhalation > solution: 100 µg per actuation in pressurized metered dose inhaler (as sulfate); 2.5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per mL in multi-dose bottle (as sulfate) for use in nebulizers	Chronic obstructive pulmonary disease Asthma

Salicylic acid

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Local > Topical > Solution: 5%	Seborrhoeic dermatitis Psoriasis of unspecified type Ichthyoses

Saquinavir

Section	Indications
Antiretrovirals > Protease inhibitors ◦ Oral > Solid: 200 mg; 500 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Selenium sulfide

Section	Indications
Dermatological medicines > Antifungal medicines ◦ Local > Topical > Suspension: 2% detergent-based	Seborrhoeic dermatitis Pityriasis versicolor

Semaglutide

Section	Indications
Hypoglycaemic agents ◦ Parenteral > General injections > SC: 0.25 mg in pre-filled pen injection solution; 0.5 mg in pre-filled pen injection solution; 1 mg in pre-filled pen injection solution; 2 mg in pre-filled pen injection solution; 4 mg in pre-filled pen injection solution ◦ Oral > Solid > tablet: 3 mg ◦ Parenteral > General injections > SC: 0.68 mg per mL; 1.34 mg per mL; 2.68 mg per mL	Obesity Type 2 diabetes mellitus

Senna

Section	Indications
Medicines for other common symptoms in palliative care ◦ Oral > Liquid: 7.5 mg per 5 mL oral liquid	Palliative care
Laxatives ◦ Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)	Constipation

Sertraline

Section	Indications
Medicines for anxiety disorders	Therapeutic equivalent to fluoxetine pour Generalised anxiety disorder

Sevoflurane

Section	Indications
General anaesthetics and oxygen > Inhalational medicines ◦ Respiratory > Inhalation > liquid:	Anaesthetics and therapeutic gases

Silver diamine fluoride

Section	Indications
Dental medicines and preparations ◦ Local > Dental > Solution: 38% w/v	Dental caries

Silver nitrate

Section	Indications
Ophthalmological preparations > Anti-infective agents ◦ Local > Ophthalmological > Solution (eye drops): 1%	Neonatal conjunctivitis or dacryocystitis

Silver sulfadiazine

Section	Indications
Dermatological medicines > Anti-infective medicines ◦ Local > Topical > Cream: 1%	Burns

Simeprevir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations ◦ Oral > Solid: 150 mg	Chronic hepatitis C

Simvastatin

Section	Indications
Lipid-lowering agents ◦ Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg	Mixed hyperlipidaemia Coronary atherosclerosis
Medicines for endocrine disorders ◦ Oral > Solid: 20 mg	Polycystic ovary syndrome

Smallpox vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against certain single viral diseases

Snake antivenom

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ .	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sodium calcium edetate

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sodium chloride

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Parenteral ◦ Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L)	Other specified disorders of fluid, electrolyte or acid-base balance

Sodium hyaluronate

Section	Indications
Ophthalmological preparations	Therapeutic equivalent to hypromellose pour Keratoconjunctivitis sicca

Sodium hydrogen carbonate

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Parenteral ◦ Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol/L and HCO3- 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L and HCO3- 1000 mmol/L)	Acidosis

Sodium nitrite

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sodium nitroprusside

Section	Indications
Antihypertensive medicines ◦ Parenteral > General injections > IV: 50 mg in ampoule powder for infusion	Hypertensive crisis

Sodium stibogluconate

Section	Indications
Antileishmaniasis medicines ◦ Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial	Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis

Sodium thiosulfate

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
Dermatological medicines > Antifungal medicines ◦ Local > Topical > Solution: 15%	Pityriasis versicolor

Sofosbuvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations ◦ Oral > Solid > tablet: 200 mg; 400 mg ◦ Oral > Solid > granules: 200 mg in sachet	Chronic hepatitis C

Sofosbuvir + velpatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations ◦ Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg ◦ Oral > Solid > granules: 150 mg + 37.5 mg in sachet; 200 mg + 50 mg in sachet	Chronic hepatitis C

Somatropin

Section	Indications
Medicines for endocrine disorders ◦ Parenteral > General injections > SC: 5 mg in cartridge powder for injection; 5 mg per mL in 2 mL cartridge	Hypoglycaemia without associated diabetes

Spectinomycin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection	**Second choix** Gonococcal infection **Autres indications** Bacterial infection of unspecified site

Spironolactone

Section	Indications
Diuretics ◦ Oral > Liquid: 25 mg per 5 mL ◦ Oral > Solid > tablet: 25 mg; 12.5 mg	Oedema Ascites
Medicines used in heart failure ◦ Oral > Solid > tablet: 25 mg	Heart failure

Stavudine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Liquid: 5 mg per 5 mL powder for oral solution ◦ Oral > Solid: 15 mg; 20 mg; 30 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Streptokinase

Section	Indications
Thrombolytic medicines ◦ Parenteral > General injections > IV: 1.5 million IU in vial powder for injection	Acute myocardial infarction

Streptomycin (injection)

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial	Multi-drug resistant Mycobacterium tuberculosis

Succimer

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ Oral > Solid: 100 mg	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sulfacetamide

Section	Indications
Ophthalmological preparations > Anti-infective agents ◦ Local > Ophthalmological > Ointment: 10% (sodium salt)	Other specified conjunctivitis

Sulfadiazine

Section	Indications
Antipneumocystosis and antitoxoplasmosis medicines ◦ Oral > Solid: 500 mg	Toxoplasmosis
Anti-infective medicines ◦ Oral > Solid: 500 mg ◦ Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt)	Bacterial infection of unspecified site

Sulfadimidine

Section	Indications
Anti-infective medicines ◦ Oral > Liquid: 500 mg per 5 mL ◦ Oral > Solid: 500 mg ◦ Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)	Bacterial infection of unspecified site

Sulfadoxine + pyrimethamine

Section	Indications
Antimalarial medicines > Medicines for chemoprevention ◦ Oral > Solid: 500 mg + 25 mg tablet ◦ Oral > Solid > dispersible tablet: 250 mg + 12.5 mg tablet	Malaria due to Plasmodium falciparum Malaria
Antimalarial medicines > Medicines for curative treatment ◦ Oral > Solid: 500 mg + 25 mg tablet	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Sulfamethoxazole + trimethoprim

Section	Indications
Antipneumocystosis and antitoxoplasmosis medicines ◦ Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule ◦ Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid ◦ Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet ◦ Oral > Solid > dispersible tablet: 100 mg + 20 mg	Pneumocystosis
Access group antibiotics ◦ Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule ◦ Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid ◦ Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet ◦ Oral > Solid > dispersible tablet: 100 mg + 20 mg ◦ Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule	**Premier choix** Infectious cystitis **Second choix** Infectious gastroenteritis or colitis without specification of infectious agent Bacterial infection of unspecified site

Sulfasalazine

Section	Indications
Disease-modifying anti-rheumatic drugs (DMARDs) ◦ Oral > Solid: 500 mg	Rheumatoid arthritis, serology unspecified
Anti-inflammatory medicines ◦ Oral > Solid: 500 mg ◦ Local > Rectal > Suppository: 500 mg ◦ Local > Rectal > Retention enema: 3 g per 100 mL	Crohn disease site Ulcerative colitis

Sumatriptan

Section	Indications
Medicines for cluster headache ◦ Parenteral > General injections > SC: 6 mg per 0.5 mL in pre-filled pen; 6 mg per 0.5 mL in pre-filled syringe	Trigeminal autonomic cephalalgias
Medicines for acute migraine attacks ◦ Oral > Solid > tablet: 50 mg	Migraine

Sunscreen, broad-spectrum

Section	Indications
Dermatological medicines ◦ Topical cream, lotion, gel, ointment, spray with sun protection factor ≥ 50.	Xeroderma pigmentosum
Dermatological medicines > Sunscreens ◦ Topical: ◦ Therapeutic broad-spectrum sunscreens should contain proven active ingredients in appropriate amounts to absorb or filter UVA and UVB radiation, and have a high sun protection factor (SPF).	Albinism or other specified genetically-determined hypomelanotic disorders

Suramin sodium

Section	Indications
Medicines for the treatment of 1st stage African trypanosomiasis ◦ Parenteral > General injections > IV: 1 g in vial	Rhodesiense trypanosomiasis
Antifilarials ◦ Parenteral > General injections > IV: 1 g in vial	Filariasis

Suxamethonium

Section	Indications
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors ◦ Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (chloride)	Muscle relaxants

Tacalcitol

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation	Therapeutic equivalent to calcipotriol pour Psoriasis of unspecified type

Tacrolimus

Section	Indications
Immunomodulators for non-malignant disease ◦ Parenteral > General injections > IV: 5 mg per mL in 1 mL vial ◦ Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension ◦ Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)	Failure or rejection of transplanted organs or tissues

Tamoxifen

Section	Indications
Hormones and antihormones ◦ Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)	Malignant neoplasms of breast Other specified malignant neoplasms of breast

Tedizolid

Section	Indications
Reserve group antibiotics	Therapeutic equivalent to linezolid pour Methicillin resistant Staphylococcus aureus Therapeutic equivalent to linezolid pour Vancomycin resistant Staphylococcus aureus Therapeutic equivalent to linezolid pour Vancomycin resistant Enterococcus

Telmisartan + amlodipine

Section	Indications
Antihypertensive medicines ◦ Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg	Essential hypertension

Telmisartan + hydrochlorothiazide

Section	Indications
Antihypertensive medicines ◦ Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg	Essential hypertension

Temozolomide

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 100 mg in vial powder for injection ◦ Oral > Solid > capsule: 5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg	Other specified gliomas of brain Neuroblastoma, NOS Unspecified malignant neoplasms of unspecified sites Ewing sarcoma of bone or articular cartilage of unspecified sites

Tenofovir alafenamide

Section	Indications
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Solid: 25 mg	Chronic hepatitis B

Tenofovir disoproxil fumarate

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)	Contact with or exposure to human immunodeficiency virus Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)	Chronic hepatitis B

Terbinafine

Section	Indications
Dermatological medicines > Antifungal medicines ◦ Local > Topical > Cream: 1% terbinafine hydrochloride ◦ Local > Topical > Ointment: 1% terbinafine hydrochloride	Fungal infection of the skin

Terbutaline

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to salbutamol pour Chronic obstructive pulmonary disease Therapeutic equivalent to salbutamol pour Asthma

Terizidone

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > capsule: 250 mg	Therapeutic equivalent to cycloserine pour Multi-drug resistant Mycobacterium tuberculosis

Testosterone

Section	Indications
Androgens ◦ Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)	Testicular dysfunction or testosterone-related disorders

Tetanus antitoxin

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ Parenteral > General injections > IM: 50000 IU in vial	Tetanus

Tetanus vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against tetanus alone

Tetracaine

Section	Indications
Ophthalmological preparations > Local anaesthetics ◦ Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)	Local anaesthetics

Tetracycline

Section	Indications
Ophthalmological preparations > Anti-infective agents ◦ Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)	Neonatal conjunctivitis or dacryocystitis Other specified conjunctivitis Infectious keratitis Infectious blepharitis Trachoma
Access group antibiotics ◦ Oral > Solid: 250 mg (hydrochloride)	Bacterial infection of unspecified site

Thalidomide

Section	Indications
Immunomodulators ◦ Oral > Solid: 50 mg	Plasma cell myeloma

Thiamine

Section	Indications
Vitamins and minerals ◦ Parenteral > General injections > IV: 50 mg per mL in ampoule or vial (hydrochloride) ◦ Oral > Solid > tablet: 50 mg (hydrochloride)	Vitamin B1 deficiency

Thiopental

Section	Indications
General anaesthetics and oxygen > Injectable medicines	Therapeutic equivalent to propofol pour Anaesthetics and therapeutic gases

Ticagrelor

Section	Indications
Anti-platelet medicines ◦ Oral > Solid > tablet: 60 mg; 90 mg	Acute ischaemic heart disease Presence of coronary angioplasty implant or graft

Tick-borne encephalitis vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against arthropod-borne viral encephalitis

Tigecycline

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 50 mg in vial powder for injection	Other specified bacterial diseases

Timolol

Section	Indications
Ophthalmological preparations > Miotics and antiglaucoma medicines ◦ Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)	Ocular hypertension Primary open-angle glaucoma

Tinidazole

Section	Indications
Antiamoebic and antigiardiasis medicines	Therapeutic equivalent to metronidazole pour Amoebiasis

Tioguanine

Section	Indications
Cytotoxic medicines ◦ Oral > Solid: 40 mg	Lymphoid leukaemia, not elsewhere classified

Tiotropium bromide

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease ◦ Respiratory > Inhalation > powder: 18 µg in capsule ◦ Respiratory > Inhalation > solution: 1.25 µg per actuation in soft mist inhaler; 2.5 µg per actuation in soft mist inhaler	Chronic obstructive pulmonary disease

Tirzepatide

Section	Indications
Hypoglycaemic agents	Therapeutic equivalent to semaglutide pour Obesity Therapeutic equivalent to semaglutide pour Type 2 diabetes mellitus

Tisagenlecleucel

Section	Indications
Antineoplastics and supportive medicines	Therapeutic equivalent to axicabtagene ciloleucel pour Diffuse large B-cell lymphomas

Tislelizumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 100 mg per 10 mL ◦ Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion ◦ Parenteral > General injections > IV: 100 mg per 10 mL contentrate for solution for infusion	Malignant neoplasms of urinary tract Squamous cell carcinoma of oesophagus Other specified malignant neoplasms of bronchus or lung Hodgkin lymphoma

Tobramycin

Section	Indications
Ophthalmological preparations > Anti-infective agents	Therapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis

Tocilizumab

Section	Indications
Medicines for juvenile joint diseases ◦ Parenteral > General injections > IV: 80 mg per 4 mL in vial; 200 mg per 10 mL in vial; 400 mg per 20 mL in vial ◦ Parenteral > General injections > SC: 162 mg per 0.9 mL in pre-filled syringe	Juvenile systemic arthritis

Tolbutamide

Section	Indications
Hypoglycaemic agents ◦ Oral > Solid: 500 mg	Type 2 diabetes mellitus

Torasemide

Section	Indications
Diuretics	Therapeutic equivalent to furosemide pour Anuria or oliguria Therapeutic equivalent to furosemide pour Oedema
Medicines used in heart failure	Therapeutic equivalent to furosemide pour Heart failure

Toripalimab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 240 mg per 6 mL in vial	Squamous cell carcinoma of oesophagus Malignant neoplasms of nasopharynx

Tramadol

Section	Indications
Opioid analgesics ◦ Oral > Liquid: 100 mg per mL (hydrochloride) ◦ Oral > Solid: 50 mg (hydrochloride) immediate release; 50 mg (hydrochloride) controlled release; 100 mg (hydrochloride) controlled release; 150 mg (hydrochloride) controlled release; 200 mg (hydrochloride) controlled release; 300 mg (hydrochloride) controlled release; 400 mg (hydrochloride) controlled release ◦ Parenteral > General injections > unspecified: 50 mg per mL in 2 mL ampoule (hydrochloride)	Chronic cancer pain

Trametinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 0.5 mg; 2 mg	Other specified melanoma of skin

Tranexamic acid

Section	Indications
Other medicines administered to the mother ◦ Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule	Postpartum haemorrhage
Medicines affecting coagulation ◦ Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule	Haemorrhage, not elsewhere classified

Trastuzumab

Section	Indications
Targeted therapies ◦ Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection	Carcinoma of breast, specialised type

Trastuzumab emtansine

Section	Indications
Targeted therapies ◦ Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection	Carcinoma of breast, specialised type

Tremelimumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion	Hepatocellular carcinoma of liver Other specified malignant neoplasms of bronchus or lung

Triamcinolone hexacetonide

Section	Indications
Medicines for juvenile joint diseases ◦ Parenteral > Locoregional injections > Intra-articular: 20 mg per mL in vial	Juvenile idiopathic arthritis

Triclabendazole

Section	Indications
Antischistosomals and other antitrematode medicines ◦ Oral > Solid > tablet: 250 mg (scored)	Paragonimiasis Fascioliasis

Trihexyphenidyl

Section	Indications
Medicines for central nervous system disorders ◦ Oral > Solid: 2 mg (hydrochloride); 5 mg (hydrochloride)	Parkinson disease
Medicines for parkinsonism	Therapeutic equivalent to biperiden pour Parkinson disease

Trimethoprim

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 50 mg per mL ◦ Oral > Solid: 100 mg; 200 mg	**Premier choix** Infectious cystitis

Triptorelin

Section	Indications
Hormones and antihormones	Therapeutic equivalent to leuprorelin pour Malignant neoplasms of breast Therapeutic equivalent to leuprorelin pour Malignant neoplasms of prostate

Tropicamide

Section	Indications
Diagnostic agents > Ophthalmic medicines ◦ Local > Ophthalmological > Solution (eye drops): 0.5%	Cycloplegic drug

Tropisetron

Section	Indications
Medicines for other common symptoms in palliative care	Therapeutic equivalent to ondansetron pour Palliative care
Antiemetic medicines	Therapeutic equivalent to ondansetron pour Nausea or vomiting

Tuberculin, purified protein derivative

Section	Indications
Immunologicals > Diagnostic agents ◦ Parenteral > Locoregional injections > Intradermal:	Mycobacterial diseases

Tubocurarine

Section	Indications
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors ◦ Parenteral > General injections > IV: 10 mg per mL in 1.5 mL ampoule (tubocurarine chloride)	Muscle relaxants

Typhoid vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against typhoid-paratyphoid alone

Ulipristal

Section	Indications
Oral hormonal contraceptives ◦ Oral > Solid: 30 mg tablet (ulipristal acetate)	Contact with health services for postcoital contraception

Umeclidinium

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to tiotropium bromide pour Chronic obstructive pulmonary disease

Urea

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Local > Topical > Cream: 10%; 5% ◦ Local > Topical > Ointment: 10%; 5%	Xerosis cutis or asteatosis
Dermatological medicines > Moisturizers ◦ Local > Topical > Cream: 5 per %	Atopic eczema

Ustekinumab

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 45 mg per 0.5 mL in pre-filled syringe; 45 mg per 0.5 mL in pre-filled pen; 90 mg per mL in pre-filled syringe; 90 mg per mL in pre-filled pen	Psoriasis of unspecified type

Valaciclovir

Section	Indications
Medicines for viral central nervous system infections	Therapeutic equivalent to aciclovir pour Zoster Therapeutic equivalent to aciclovir pour Herpes simplex infections Therapeutic equivalent to aciclovir pour Varicella

Valganciclovir

Section	Indications
Other antivirals ◦ Oral > Liquid: 50 mg per mL (as hydrochloride) powder for oral solution ◦ Oral > Solid > tablet: 450 mg (as hydrochloride)	Cytomegaloviral retinitis

Valproic acid (sodium valproate)

Section	Indications
Antiseizure medicines ◦ Oral > Liquid: 200 mg per 5 mL ◦ Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable) ◦ Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 3 mL ampoule	Epilepsy or seizures Status epilepticus
Medicines for bipolar disorders ◦ Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)	Bipolar or related disorders

Valsartan + amlodipine + hydrochlorothiazide

Section	Indications
Antihypertensive medicines ◦ Oral > Solid > dosage form: 160 mg + 5 mg + 12.5 mg; 160 mg + 5 mg + 25 mg; 160 mg + 10 mg + 12.5 mg; 160 mg + 10 mg + 25 mg; 320 mg + 10 mg + 25 mg	Essential hypertension

Vancomycin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection ◦ Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride) ◦ Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection ◦ Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection	**Premier choix** Necrotising fasciitis co-prescrite avec ceftazidime Endophthalmitis co-prescrite avec ceftriaxone Endophthalmitis **Second choix** Intestinal infections due to Clostridioides difficile Neutropaenia (high-risk) **Autres indications** Methicillin resistant Staphylococcus aureus

Varenicline

Section	Indications
Medicines for nicotine use disorders ◦ Oral > Solid: 0.5 mg; 1 mg	Nicotine dependence

Varicella vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against certain single viral diseases

Vecuronium

Section	Indications
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors ◦ Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)	Muscle relaxants

Vemurafenib

Section	Indications
Targeted therapies	Therapeutic equivalent to dabrafenib pour Other specified melanoma of skin

Verapamil

Section	Indications
Antianginal medicines ◦ Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)	Angina pectoris
Medicines for cluster headache ◦ Oral > Solid > tablet: 120 mg (hydrochloride) (immediate-release); 40 mg (hydrochloride) (immediate-release); 80 mg (hydrochloride) (immediate-release); 120 mg (hydrochloride) (extended-release); 180 mg (hydrochloride) (extended-release); 240 mg (hydrochloride) (extended-release)	Trigeminal autonomic cephalalgias
Antiarrhythmic medicines ◦ Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride) ◦ Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)	Supraventricular tachyarrhythmia

Vinblastine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate) ◦ Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)	Other specified gliomas of brain Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis Kaposi sarcoma of unspecified primary site Germ cell tumour of testis Other specified malignant neoplasms of the ovary Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma

Vincristine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate) ◦ Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)	Other specified gliomas of brain Diffuse large B-cell lymphoma, not otherwise specified Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Langerhans cell histiocytosis Kaposi sarcoma of unspecified primary site Rhabdomyosarcoma primary site Hodgkin lymphoma Unspecified malignant neoplasms of unspecified sites Malignant trophoblastic neoplasms of placenta Follicular lymphoma Ewing sarcoma of bone or articular cartilage of unspecified sites Retinoblastoma Malignant neoplasms of kidney, except renal pelvis

Vinorelbine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial ◦ Oral > Solid > capsule: 20 mg; 30 mg; 80 mg ◦ Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial	Rhabdomyosarcoma primary site Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast

Voriconazole

Section	Indications
Antifungal medicines ◦ Parenteral > General injections > IV: 200 mg in vial powder for injection ◦ Oral > Liquid: 40 mg per mL powder for oral liquid ◦ Oral > Solid: 50 mg tablet; 200 mg tablet	Chronic pulmonary aspergillosis Invasive aspergillosis

Warfarin

Section	Indications
Medicines affecting coagulation ◦ Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium) ◦ Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)	Venous thromboembolism Cerebral ischaemic stroke due to embolic occlusion Atrial fibrillation Other specified diseases of arteries or arterioles

Water for injection

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous ◦ Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule	Unspecified appropriateness of dosing or administration without injury or harm

Whole blood

Section	Indications
Blood and blood components ◦ Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

Xylometazoline

Section	Indications
Ear, nose and throat medicines [c] ◦ Local > Nasal > Spray: 0.05% equivalent to 0.5 mg per mL ◦ Local > Nasal > Drops: 0.05% equivalent to 0.5 mg per mL	Nasal congestion

Yellow fever vaccine

Section	Indications
Immunologicals > Vaccines ◦ All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against certain single viral diseases

Zanubrutinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 80 mg ◦ Oral > Solid > capsule: 80 mg	Mantle cell lymphoma Therapeutic equivalent to ibrutinib pour Chronic lymphocytic leukaemia or small lymphocytic lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Zidovudine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion ◦ Oral > Liquid: 50 mg per 5 mL ◦ Oral > Solid > tablet: 300 mg ◦ Oral > Solid > capsule: 250 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Zinc sulfate

Section	Indications
Medicines for diarrhoea ◦ Oral > Solid > dispersible tablet: 20 mg (scored)	Diarrhoea

Zoledronic acid

Section	Indications
Medicines for endocrine disorders ◦ Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle	Osteogenesis imperfecta
Supportive medicines ◦ Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle	Malignant neoplasm metastasis in bone or bone marrow

Zuclopenthixol decanoate

Section	Indications
Medicines for psychotic disorders	Therapeutic equivalent to fluphenazine pour Schizophrenia or other primary psychotic disorders